

Grants Opportunities: Health & Human Services (121)

Dec. 2014 - March 2015

Planning Program and Local Technical Assistance Program

Granting Agency: Department of Commerce

Current Closing Date: Applications are accepted on a continuing basis and processed as received. This Planning and Local Technical Assistance opportunity will remain in effect until superseded by a future announcement.

Expected Number of Awards: 425

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Private institutions of higher education; Public and State controlled institutions of higher education; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification)

Estimated Total Program Funding: \$100,000

CFDA Number: 11.302, 11.303,

Funding Opportunity Number: EDAPLANNING2012

Pursuant to PWEDA, EDA announces general policies and application procedures for grant-based investments under the Planning and Local Technical Assistance programs. Under the Planning program EDA assists eligible recipients in creating regional economic development plans designed to stimulate and guide the economic development efforts of a community or region. As part of this program, EDA supports Partnership Planning investments to facilitate the development, implementation, revision, or replacement of Comprehensive Economic Development Strategies (CEDS), which articulate and prioritize the strategic economic goals of recipients' respective regions. In general, EDA provides Partnership Planning grants to the designated planning organization (e.g., District Organization) serving EDA-designated Economic Development Districts to enable these organizations to develop and implement relevant CEDS. In addition, EDA provides Partnership Planning grants to Indian Tribes to help develop and implement CEDS and associated economic development activities. The Planning program also helps support planning organizations, including District Organizations, Indian Tribes, and other eligible Recipients, with Short Term and State Planning investments designed to guide the eventual creation and retention of higher-skill, higher-wage jobs, particularly for the unemployed and underemployed in the Nation's most economically distressed regions. The Local Technical Assistance program strengthens the capacity of local or State organizations, institutions of higher education, and other eligible recipients to undertake and promote effective economic development programs through projects such as feasibility analyses and impact studies.

Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: 12/02/2014

Expected Number of Awards: 6

Eligibility: For profit organizations other than small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Private institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

Estimated Total Program Funding: \$2,000,000

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-011

The purpose of this Funding Opportunity Announcement (FOA) is to establish the second phase of the Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) through a cooperative agreement. The CKD BioCon was established as a cooperative agreement in September 2009 as a result of RFA-DK-08-015 [Chronic Kidney Disease Biomarker Discovery and Validation Consortium (U01)] to discover, develop, validate and qualify biomarkers based on existing stored or repositied biosamples from well-characterized CKD patients with longitudinal follow-up. The current CKD BioCon consists of six Participating Centers (PCs) and is actively engaged in multiple research protocols. The next phase of the CKD BioCon will continue a multicenter consortium to identify new biomarkers or rigorously validate already identified biomarkers for chronic kidney diseases, consisting of successful applicants to this FOA. Application for the second phase of the CKD BioCon will be open to members of the original consortium as well as new investigative teams.) **For more information, go to <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-011.html>**

Limited Competition: Data Coordinating Center for The Environmental Determinants of Diabetes in the Young

Granting Agency: National Institutes of Health

Current Closing Date for Applications: 12/02/2014

Expected Number of Awards: 1

Eligibility: Eligible Applicants include the following: Only the currently awardee for RFA-12-510 is eligible to apply to this Funding Opportunity Announcement. Foreign Institutions Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-

U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Estimated Total Program Funding: \$20,000,000

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-505

This Funding Opportunity Announcement (FOA) invites one High Impact Research and Research Infrastructure Cooperative Agreement application (UC4) from the Program Director/Principal Investigator (PD/PI) of the Data Coordinating Center (DCC) from RFA-DK-12-510 that has been involved in study design and coordination, and data and biosample acquisition and management, since the inception of The Environmental Determinants of Diabetes in the Young (TEDDY) consortium, an ongoing epidemiological study. This is a one-time FOA to support the TEDDY DCC to establish an open competition for collaborators for Big Data analysis. Successful collaborators will need to have the capability to integrate data across many types, including multi-omics, diet records, clinical data, environmental analytes, and other data. The data and the data analytics tools will need to be available to TEDDY investigators using optimal means for sharing that could include a secure cloud environment. In addition, this FOA is intended to support the TEDDY DCC for subject follow-up in the final year of the award. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-505.html>

Service Area Competition

Granting Agency: Health Resources & Services Administration

Current Closing Date for Applications: Dec 3, 2014

Expected Number of Awards: 38

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), City or township governments, Public housing authorities/Indian housing authorities, Independent school districts

Estimated Total Program Funding: \$100,975,803

CFDA Number: 93.224 -- Consolidated Health Centers (Community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public

Funding Opportunity Number: HRSA-15-015

Health centers improve the health of the Nation's underserved communities and vulnerable populations by ensuring access to comprehensive, culturally competent, quality primary health care services. Health Center Program grants support a variety of community-based and patient-directed public and private nonprofit organizations that serve an increasing number of the Nation's underserved. Individually, each health center plays an important role in the goal of ensuring access to services, and combined, they have had a critical impact on the health care status of medically underserved and vulnerable populations throughout the United States and its territories. The Health Center Program targets the Nation's neediest populations and geographic areas by currently funding approximately 1,300 health centers that operate over 9,000 service delivery sites in every state, the District of Columbia, Puerto Rico, the Virgin Islands, and the Pacific Basin. In 2013, more than 21 million patients, including medically underserved and uninsured patients, received comprehensive, culturally competent, quality primary health care services through the Health Center Program. This Funding Opportunity Announcement (FOA) solicits applications for the Health Center Program's Service Area Competition (SAC). The

FOA details the SAC eligibility requirements, review criteria, and awarding factors for organizations seeking a grant for operational support of an announced service area under the Health Center Program, including Community Health Center (CHC ; section 330(e)), Migrant Health Center (MHC ; section 330(g)), Health Care for the Homeless (HCH ; section 330(h)), and/or Public Housing Primary Care (PHPC ; section 330(i)). For the purposes of this document, the term ;health center; refers to the diverse types of health centers (i.e., CHC, MHC, HCH, and /or PHPC) supported under section 330 of the PHS Act, as amended. **For more information**, Contact Beth Hartmayer at (301)594-4300 or email BPHCSAC@hrsa.gov

Specialized Alcohol Research Centers (P50)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Dec 3, 2014

Expected Number of Awards: _

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses, Public and State controlled institutions of higher education, Independent school districts, Small businesses, Native American tribal governments (Federally recognized), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities, Private institutions of higher education

Estimated Total Program Funding: \$7,400,000

CFDA Number: 93.273 -- Alcohol Research Programs

Funding Opportunity Number: RFA-AA-15-001

This Funding Opportunity Announcement (FOA) invites applications for specialized Alcohol Research Centers using the P50 mechanism. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic consequences across the lifespan. Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-15-001.html>

Comprehensive Alcohol Research Centers (P60)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: 12/03/2014

Expected Number of Awards:

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses, Public and State controlled institutions of higher education, Independent school districts, Small businesses, Native American tribal governments (Federally recognized), Nonprofits having a 501(c)(3)

status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities, Private institutions of higher education.

Estimated Total Program Funding: \$7,400,000

CFDA Number: 93.273 -- Alcohol Research Programs

Funding Opportunity Number: RFA-AA-15-002

This Funding Opportunity Announcement (FOA) invites applications for Comprehensive Alcohol Research Centers using the P60 mechanism that must include an information dissemination core to initiate and expand community education, related to the overall goal of the center. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic consequences across the lifespan. Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-15-002.html>

The National Drug Abuse Treatment Clinical Trials Network (UG1)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Dec 3, 2014

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses, Public and State controlled institutions of higher education, Independent school districts, Small businesses, Native American tribal governments (Federally recognized), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities, Private institutions of higher education.

Estimated Total Program Funding: \$15,000,000

CFDA Number: 93.279 -- Drug Abuse and Addiction Research Programs

Funding Opportunity Number: RFA-DA-15-008

This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN). NIDA intends to expand its research to develop and test interventions for the management of the wide spectrum of substance use disorders (SUD) with input from and collaboration with clinical research investigators, healthcare providers, patients and relevant stakeholders. It is expected that successful applicants will describe working alliances with existing and newly created practice-based primary care or other general medical research networks. Through such collaborations, the expanded CTN will execute a comprehensive and staged treatment research agenda to generate the research evidence needed for the integrated management of patients with substance misuse/SUD at general medical settings and linked specialty care treatment settings. This expansion of the CTN also provides an opportunity for community-based SUD treatment provider partners to evaluate integrated and collaborative treatment models for the management of patients with higher-severity SUDs. Together, the CTN will produce much needed, high integrity, evidence-based interventions for a range of substance use problems with the goal of

improving the health outcomes of this Nation. **For more information, go to:**
<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-008.html>

Type 1 Diabetes TrialNet Clinical Centers (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Dec 3, 2014

Expected Number of Awards:

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses, Public and State controlled institutions of higher education, Independent school districts, Small businesses, Native American tribal governments (Federally recognized), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities, Private institutions of higher education.

Estimated Total Program Funding: \$2,000,000

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-016

Type 1 Diabetes TrialNet is an international consortium of clinical research centers aimed at the delay or prevention of type 1 diabetes (T1D). This Funding Opportunity Announcement (FOA) will provide infrastructure support for TrialNet Centers, allowing them to recruit treat, and follow subjects in TrialNet studies and trials. In additional, funding will be provided for Clinical Centers to support Affiliate Sites. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-016.html>

Limited Competition: Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Dec 3, 2014

Expected Number of Awards:

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses, Public and State controlled institutions of higher education, Independent school districts, Small businesses, Native American tribal governments (Federally recognized), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities, Private institutions of higher education.

Estimated Total Program Funding: \$45,000,000

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-507

This Funding Opportunity Announcement (FOA) invites a Research Project Cooperative Agreement application (UC4) from the Program Director/Principal Investigator of the Data Coordinating Center (DCC) that is currently managing this large, complex and effective network. This FOA will support new activities, such as a new Biomarker and Mechanisms Panel, to

design and possibly implement mechanistic studies using TrialNet subjects and samples, support new approaches to improve TrialNet recruiting and collaboration in partnership with the Clinical Network Hub, support the design and conduct of new prevention trials (as selected by the TrialNet Steering Committee) to replace ongoing trials, or new trials in newly described at-risk populations, and support the design and conduct of new studies in a silent diabetes population (as selected by the TrialNet Steering Committee). In the final 2 years of the award, this FOA will provide funds to continue the ongoing efforts of TrialNet. The DCC will support a wide range of research projects in varying stages of development, implementation and completion. The DCC will provide for data and sample management, including standardized acquisition, quality control, dissemination, and public accessibility. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-507.html>

Pathogen Predators

Granting Agency: DARPA

Current Closing Date for Applications: Dec 9, 2014

Eligibility: Unrestricted

CFDA Number: 19.009 -- Academic Exchange Programs - Undergraduate Programs

Funding Opportunity Number: DARPA-BAA-14-51

DARPA is soliciting proposals for research supporting the potential use of Bdellovibrio and/or Micavibrio bacterial predators as therapeutics against infections caused by Gram-negative antibiotic-resistant and priority threat pathogens.

Current Closing Date for Applications: Dec 17, 2014

Expected Number of Awards: 25

Eligibility: Eligible applicants include public and private entities, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C. 450b), faith-based organizations, and community-based organizations. The law limits the site of eligible organizations to the 50 States and the District of Columbia. Although Tribes and tribal organizations may apply, they must meet all applicable requirements, including targeting all CYSHCN across the State for services.

Estimated Total Program Funding: \$25,000,000

CFDA Number: 12.420 -- Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-BCRP-BREAKTHROUGH2-FL12

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement.

Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. **For more information, go to:** <https://www.fbo.gov/spg/ODA/DARPA/CMO/DARPA-BAA-14-51/listing.html>

Obstetric-Fetal Pharmacology Research Centers (OPRC) (U54)

Granting Agency: National Institutes of Health
Current Closing Date for Applications: Dec 9, 2014
Expected Number of Awards:

Eligibility: For profit organizations other than small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Private institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

Estimated Total Program Funding: \$4,800,000

CFDA Number: 93.865 -- Child Health and Human Development Extramural Research

Funding Opportunity Number: RFA-HD-14-013

The purpose of this funding opportunity announcement (FOA) is to announce the competition of the Obstetric-Fetal Pharmacology Research Centers (OPRC) - a specialized cooperative multicenter program in the obstetric pharmacology research. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) proposes to fund a limited number of research centers which will provide an arena for multidisciplinary interactions among basic and clinical scientists interested in establishing high quality translational research programs in the area of obstetric pharmacology. The centers will also serve as national resources for clinical pharmacological research in women during normal and abnormal pregnancies. Center investigators will be expected to work with NICHD staff in facilitating research collaborations and interactions within and among the centers. Such a cooperative program will form a national network that facilitates the translation of knowledge from the basic sciences into the development of new treatments, and findings from clinical studies/trials into practice with ultimate goal of improving the safety and effectiveness of the medical treatment in pregnant women. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-14-013.html>

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21)

Granting Agency: National Institutes of Health
Current Closing Date for Applications: Dec 15, 2014
Expected Number of Awards:

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Small businesses, Native American tribal organizations (other than Federally recognized tribal governments), Private institutions of higher education, Public and State controlled institutions of higher education, Independent school districts, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities For profit organizations other than small businesses

Estimated Total Program Funding: \$2,000,000

CFDA Number: 93.279 -- Drug Abuse and Addiction Research Programs

Funding Opportunity Number: RFA-DA-15-012

The purpose of this FOA is to encourage research projects that investigate extracellular vesicles in HIV infection/progression or as potential HIV/AIDS biomarkers or therapeutics. Proposed projects must also explore the potential impact of exposure to substances of abuse. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-012.html>

Family-to-Family Health Information Centers

Granting Agency: Health Resources & Services Administration

Current Closing Date for Applications: Dec 16, 2014

Expected Number of Awards: 51

Eligibility: Eligible applicants include public and private entities, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C. 450b), faith-based organizations, and community-based organizations. The law limits the site of eligible organizations to the 50 States and the District of Columbia. Although Tribes and tribal organizations may apply, they must meet all applicable requirements, including targeting all CYSHCN across the State for services.

Estimated Total Program Funding: \$5,000,000

CFDA Number: 93.504 -- Family to Family Health Information Centers

Funding Opportunity Number: HRSA-15-114

This announcement solicits applications for the Family-to-Family Health Information Centers (F2F HICs or "the Centers") Program. The purpose of this grant program is to provide information, education, technical assistance, and peer support to families of children and youth with special health care needs (CYSHCN) and professionals who serve such families.

For more information, go to: HRSA Grants Application Center, 910 Clopper Road, Suite 155 South, Gaithersburg, MD, 20878 LSmalley@hrsa.gov

Children's Environmental Health and Disease Prevention Research Centers (P50)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Dec 22, 2014

Expected Number of Awards: 5

Eligibility: For profit organizations other than small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Private institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

Estimated Total Program Funding: \$7,000,000

CFDA Number: 93.113 -- Environmental Health

Funding Opportunity Number: RFA-ES-14-002

This Funding Opportunity Announcement (FOA) encourages grant applications to support a transdisciplinary program of basic and applied research to examine the effects of environmental factors on children's health and well-being. Research conducted through the Centers should include substantive areas of science in children's health while incorporating innovative technologies and approaches and links to the environment. This program encourages strong links between disciplines in the basic, applied, clinical and public health sciences to prevent disease and promote health of all children. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-14-002.html>

Family-to-Family Health Information Centers

Granting Agency: Health Resources & Services Administration

Current Closing Date for Applications: Dec 23, 2014

Expected Number of Awards: 51

Eligibility: Eligible applicants include public and private entities, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C. 450b), faith-based organizations, and community-based organizations. The law limits the site of eligible organizations to the 50 States and the District of Columbia. Although Tribes and tribal organizations may apply, they must meet all applicable requirements, including targeting all CYSHCN across the State for services.

Estimated Total Program Funding: \$5,000,000

CFDA Number: 93.504 -- Family to Family Health Information Centers

Funding Opportunity Number: HRSA-15-114

This announcement solicits applications for the Family-to-Family Health Information Centers (F2F HICs or the Centers) Program. The purpose of this grant program is to provide information, education, technical assistance, and peer support to families of children and youth with special health care needs (CYSHCN) and professionals who serve such families.

For more information, go to: HRSA Grants Application Center, 910 Clopper Road, Suite 155 South, Gaithersburg, MD, 20878 L.Smalley@hrsa.gov

NeuroNEXT Infrastructure Resource Access (X01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Dec 30, 2014

Expected Number of Awards: 2

Eligibility: Small businesses, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses

Estimated Total Program Funding: \$400,000

CFDA Number: 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders

Funding Opportunity Number: PAR-11-344

This announcement solicits applications for the Family-to-Family Health Information Centers (F2F HICs or the Centers) Program. The purpose of this grant program is to provide information, education, technical assistance, and peer support to families of children and youth with special health care needs (CYSHCN) and professionals who serve such families. For more information, go to: <http://grants.nih.gov/grants/guide/pa-files/PA-11-344.html>

Technology-Based Interventions to Promote Engagement in Care and Treatment Adherence and For Substance Abusing Populations with HIV (R34)

Granting Agency: National Institutes of Health
Current Closing Date for Applications: Dec 30, 2014
Expected Number of Awards:

Eligibility: : For profit organizations other than small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Private institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

Estimated Total Program Funding: \$225,000

CFDA Number: 93.279 -- Drug Abuse and Addiction Research Programs

Funding Opportunity Number: PA-12-118

This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) encourages Clinical Trial Planning Grant (R34) applications to develop, pilot test and determine the feasibility of technology tools, including mobile devices, to promote engagement in Human Immunodeficiency Virus (HIV) care among substance abusing populations with HIV. Research projects may focus on: (a) the use of technology to directly improve patient-level outcomes (i.e., adherence); (b) the capacity of HIV treatment providers and related service delivery organizations to adopt and integrate such technologies to promote HIV treatment outcomes; or (c) the use of technology to improve the organization and delivery of HIV treatment and services. For more information, go to: <http://grants.nih.gov/grants/guide/pa-files/PA-12-118.html>

Technology-Based Interventions to Promote Engagement in Care and Treatment

Adherence and For Substance Abusing Populations with HIV (R34)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Dec 30, 2014

Expected Number of Awards:

Eligibility: : For profit organizations other than small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Private institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

Estimated Total Program Funding: \$225,000

CFDA Number: 93.279 -- Drug Abuse and Addiction Research Programs

Funding Opportunity Number: PA-12-118

This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) encourages Clinical Trial Planning Grant (R34) applications to develop, pilot test and determine the feasibility of technology tools, including mobile devices, to promote engagement in Human Immunodeficiency Virus (HIV) care among substance abusing populations with HIV. Research projects may focus on: (a) the use of technology to directly improve patient-level outcomes (i.e., adherence); (b) the capacity of HIV treatment providers and related service delivery organizations to adopt and integrate such technologies to promote HIV treatment outcomes; or (c) the use of technology to improve the organization and delivery of HIV treatment and services. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-12-118.html>

NIA MSTEM: Advancing Diversity in Aging Research (ADAR) through Undergraduate Education (R25)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan 1, 2015

Expected Number of Awards:

Eligibility: Others (see text field entitled "Additional Information on Eligibility" for clarification) Public and State controlled institutions of higher education, Private institutions of higher education

Estimated Total Program Funding: \$1,400,000

CFDA Number: 93.866 -- Aging Research

Funding Opportunity Number: PAR-12-016

This funding opportunity announcement (FOA) issued by the National Institute on Aging (NIA), NIA MSTEM: Advancing Diversity in Aging Research (ADAR) through Undergraduate

Education, encourages institutional Research Education Grant (R25) applications from institutions that propose creative and innovative research education programs to diversify the workforce in aging by (1) supporting undergraduate competency and completion in medicine, science, technology, engineering and mathematics) ((MSTEM) to be referred to as NIA MSTEM fields henceforth), as they relate to aging and, also, by (2) application and transition to graduate study that advances a cadre of students from diverse backgrounds into NIA MSTEM fields. The interests of the NIA span biological, biomedical, behavioral, clinical and social sciences research across the lifespan with a focus on processes of aging through midlife and into old age. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-12-016.html>

HIV Incidence Assays with Improved Specificity (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Small businesses; Faith-based or Community-based organizations; Independent school districts.

CFDA Number: 93.855 – Allergy, Immunology and Transplantation Research 93.856 – Microbiology and Infectious Diseases Research

Funding Opportunity Number: PA-12-012

This FOA issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, encourages grant applications from institutions/ organizations that propose to develop improved HIV Incidence Assays with increased specificity and reliability for distinguishing incident from chronic HIV infections.

NIDR Clinical Trial Implementation or Biomarker Clinical Evaluation Study Cooperative Agreement (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan 7, 2015

Eligibility: Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent School Districts; Public Housing Authorities/Indian Housing Authorities; Faith-based or Community-based Organizations; Regional Organizations; Private institutions of higher education; For profit organizations other than small businesses.

CFDA Number: 93.121 – Oral Diseases and Disorders Research

Funding Opportunity Number: PAR-11-339

This FOA issued by the National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, will support investigator-initiated Phase I, II, III or IV clinical trial cooperative agreement applications or biomarker evaluation studies that require prospective collection of clinical outcomes and clinical specimens. All applicants must have received an NIDCR Clinical Trial Planning (R34) award to plan the proposed cooperative agreement study (see PAR-11-338 for information about NIDCR Clinical Trial or Biomarker Clinical Evaluation Study Planning Grants). NIDCR may consider an exception. A unique application is required for each proposed study, and must include a final draft of the study protocol, a Manual of Procedures and other supporting materials such as the Investigators Brochure. These documents must meet all National Institutes of Health (NIH), Food and Drug Administration (FDA), and Office of Human Research Protections (OHRP) requirements. All awards will be made as cooperative agreements. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-11-339.html>

Alzheimer's Disease Drug Development Program (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public housing authorities/Indian housing authorities; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Private institutions of higher education; Small businesses; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

CFDA Number: 93.866 – Aging Research

Funding Opportunity Number: PAR-12-015

The goal of this funding opportunity announcement (FOA) is to support pre-clinical development of new therapies aimed at modifying the behavioral symptoms in Alzheimer's disease (AD); or delaying the onset or slowing the progression of AD, mild cognitive impairment (MCI), or age-related cognitive decline. This program is specifically directed at projects focused on the optimization of therapeutic leads with demonstrated activity against an intended disease target. Projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the funding period. The program does not support early-stage therapeutic discovery activities such as high throughput screening. The program also excludes clinical research and basic, mechanistic research. This is a milestone-driven cooperative agreement program involving participation of NIA program staff both in the development of the project plan and monitoring of research progress. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-12-015.html>

NIA MSTEM: Advancing Diversity in Aging Research (ADAR) through Undergraduate Education (R25)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public and State controlled institutions of higher education; Private institutions of higher education.

CFDA Number: 93.866 – Aging Research

Funding Opportunity Number: PAR-12-016

This funding opportunity announcement (FOA) issued by the National Institute on Aging (NIA), NIA MSTEM: Advancing Diversity in Aging Research (ADAR) through Undergraduate Education, encourages institutional Research Education Grant (R25) applications from institutions that propose creative and innovative research education programs to diversify the workforce in aging by (1) supporting undergraduate competency and completion in medicine, science, technology, engineering and mathematics) ((MSTEM) to be referred to as NIA MSTEM fields henceforth), as they relate to aging and, also, by (2) application and transition to graduate study that advances a cadre of students from diverse backgrounds into NIA MSTEM fields. The interests of the NIA span biological, biomedical, behavioral, clinical and social sciences research across the lifespan with a focus on processes of aging through midlife and into old age. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-12-016.html>

Implications of the Economic Downturn for Health, Wealth, and Work at Older Ages (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; State governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education.

CFDA Number: 93.866 – Aging Research

Funding Opportunity Number: PAR-12-009

This Funding Opportunity Announcement (FOA) invites research on the implications of exogenous shocks, such as those produced by the recent economic downturn, for health, economic circumstances, and planning throughout the life-cycle. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-12-009.html>

Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Small businesses; Public and State controlled institutions of higher education; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

CFDA Number: 93.394 – Cancer Detection and Diagnosis Research 93.395 – Cancer Treatment Research

Funding Opportunity Number: PAR-12-014

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages the submission of Exploratory/Developmental Research Project Grant (R21) applications from institutions and organizations to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. The Cancer Diagnosis Program (CDP) and the Cancer Therapy Evaluation Program (CTEP) at the NCI are cooperatively sponsoring this FOA with the purpose to transition of candidate biomarkers from initial correlative observations into diagnostics that are suitable for use in clinical trials to assess the clinical validity of a marker. This program will support pilot research projects to improve clinical decision-making in the care of cancer patients and as such will support studies that use tumor specimens linked to specific treatment and clinical outcome information. This FOA is not appropriate for molecular diagnostics discovery projects. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-014.html>

Short Courses on Mathematical, Statistical, and Computational Tools for Studying Biological Systems (R25)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Small businesses; Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; Independent school districts; Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

CFDA Number: 93.859 – Biomedical Research and Research Training

Funding Opportunity Number: PA-11-351

This FOA issued by the National Institute of General Medical Sciences encourages applications for Research Education Grants (R25) from institutions and organizations to conduct workshops and short courses to improve integration of mathematical, statistical, and computational approaches into biological and/or behavioral research. Support will be limited to activities that reach a wide audience of researchers. The FOA is NOT intended for university courses or curriculum development. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PA-11-351.html>

NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Independent school districts; Public housing authorities/Indian housing authorities; Small businesses; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.

CFDA Number: 9393.121 – Oral Diseases and Disorders Research

Funding Opportunity Number: PAR-12-004

The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly-qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. To achieve these objectives, the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators will support two phases of research: a mentored intramural phase of up to two years, and an independent extramural phase of up to three years. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardees research program as determined by an NIDCR progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-004.html>

Pilot and Feasibility Clinical Research Grants in Kidney or Urologic Diseases (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses;

Public and State controlled institutions of higher education; Private institutions of higher education; Independent school districts; For profit organizations other than small businesses.
CFDA Number: 93.847 – Diabetes, Digestive, and Kidney Diseases Extramural Research.

Funding Opportunity Number: PAR-11-352

This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney or urologic disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney or urologic diseases. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-11-352.html>

Pilot Studies in Pancreatic Cancer (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For profit organizations other than small businesses.

CFDA Number: 93.393 – Cancer Cause and Prevention Research; 93.394 – Cancer Detection and Diagnosis Research; 93.395 – Cancer Treatment Research; 93.396 – Cancer Biology Research; 93.399 – Cancer Control.

Funding Opportunity Number: PA-11-297

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), encourages the submission of Research Project Grant (R21) applications from institutions and organizations that propose to promote innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PA-11-297.html>

Pilot Studies in Pancreatic Cancer (R03)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Private institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.

CFDA Number: 93.393 – Cancer Cause and Prevention Research; 93.394 – Cancer Detection and Diagnosis Research; 93.395 – Cancer Treatment Research; 93.396 – Cancer Biology Research; 93.399 – Cancer Control.

Funding Opportunity Number: PA-11-298

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), encourages the submission of Small Research Grant (R03) applications from institutions and organizations that propose to promote innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-298.html>

Center of Excellence for Research on CAM (P01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education.

CFDA Number: 93.213 – Research and Training in Complementary and Alternative Medicine

Funding Opportunity Number: PAR-13-220

This funding opportunity announcement (FOA) encourages the submission of applications that propose to conduct research that is of high-priority to NCCAM that requires synergistic collaboration between outstanding scientists and the synthesis of multiple research approaches by multi-disciplinary research teams. The Center of Excellence for Research on CAM (CERC) program is designed to support research in which the funding of three or four synergistic, highly meritorious projects as a group offers significant scientific advantages over support of the same projects as individual research grants. Each CERC must consist of, throughout the duration of the award, a minimum of three research projects, focused on basic, mechanistic, and/or translational research questions relevant to the research priorities described in the current NCCAM Strategic Plan. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-13-220.html>

NINDS Exploratory/Developmental Projects in Translational Research (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Private institutions of higher education; Public and State controlled institutions of higher education.

CFDA Number: 93.853 – Extramural Research Programs in the Neurosciences and Neurological Disorders

Funding Opportunity Number: PAR-13-023

The goal of this Funding Opportunity Announcement (FOA) is to support any research activities required to advance candidate therapeutics through Investigational New Drug (IND), Investigational Device Exemption (IDE), or 510(K) submission to the Food and Drug Administration (FDA), and ready them for clinical testing for neurological disorders. Projects should include a strong biological rationale for the intended approach, supporting data from rigorously designed experiments, and proposed studies that exhibit methodological rigor. Such projects, if successful, should lead directly to or support another project (e.g. cooperative agreement in translational research) that will include all remaining activities for submission of an IND, IDE, or 510(k) application to the FDA. The scope includes only preclinical development activities for therapeutic drugs, devices, and biologics; development of diagnostics or rehabilitation strategies cannot be supported. Clinical research, basic research, and studies of disease mechanism are outside the program scope. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-023.html>

Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public housing authorities/Indian housing authorities; Small businesses; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRs, other than institutions of higher education; Public and State controlled institutions of higher education; For profit organizations other than small businesses.

CFDA Number: 93.394 – Cancer Detection and Diagnosis Research; 93.395 – Cancer Treatment Research

Funding Opportunity Number: PA-12-013

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages the submission of Research Project Grant (R01) applications from institutions and organizations to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. The Cancer Diagnosis Program (CDP) and the Cancer Therapy Evaluation Program (CTEP) at the NCI are cooperatively sponsoring this FOA with the purpose to transition of candidate biomarkers from initial correlative observations into diagnostics that are suitable for use in clinical trials to assess the clinical validity of a marker. This program will support research

projects to improve clinical decision-making in the care of cancer patients and as such will support studies that use tumor specimens linked to specific treatment and clinical outcome information. This FOA is not appropriate for molecular diagnostics discovery projects. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-12-013.html>

Collaborations with National Centers for Biomedical Computing (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Small businesses; Public and State controlled institutions of higher education; Private institutions of higher education; Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations; Hispanic-serving institutions.

CFDA Number: 93.113 – Environmental Health; 93.172 – Human Genome Research; 93.233 – National Center on Sleep Disorders Research; 93.242 – Mental Health Research – 93.273 – Alcohol Research Programs; 93.286 – Discovery and Applied Research for Technological Innovations to Improve Human Health; 93.393 – Cancer Cause and Prevention Research; 93.394 – Cancer Detection and Diagnosis Research; 93.395 – Cancer Treatment Research; 93.396 – Cancer Biology Research; 93.397 – Cancer Centers Support Grants; 93.398 – Cancer Research Manpower; 93.399 – Cancer Control; 93.837 – Cardiovascular Diseases Research; 93.838 – Lung Diseases Research; 93.839 – Blood Diseases Resources Research; 93.847 – Diabetes, Digestive, and Kidney Diseases Extramural Research; 93.859 – Biomedical research and Research Training.

Funding Opportunity Number: PAR-12-001

This funding opportunity announcement (FOA) is for projects from individual investigators or small groups to collaborate with the NIH Common Fund for Medical Research National Centers for Biomedical Computing (NCBCs). For a description of the NCBCs see <http://www.ncbcs.org/>. The intention of the collaborating projects is to engage researchers across the nation in building an excellent biomedical computing environment, using the computational tools and biological and behavioral application drivers of the funded NCBCs as foundation stones. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-12-001.html>

PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Small businesses.

CFDA Number: 93.113 – Environmental Health; 93.121 – Oral Diseases and Disorders Research; 93.172 – Human Genome Research; 93.173 – Research Related to Deafness and Communication Disorders; 93.213 – Research and Training in Complementary and Alternative Medicine; 93.233 – National Center on Sleep Disorders Research; 93.242 – Mental Health Research Grants; 93.273 – Alcohol Research Programs; 93.279 – Drug Abuse and Addiction Research Programs; 93.286 – Discovery and Applied Research for Technological Innovations to Improve Human Health; 93.307 – Minority Health and Health Disparities Research; 93.350 – National Center for Advancing Translational Sciences; 93.351 – Research Infrastructure Programs; 93.361 – Nursing Research; 93.393 – Cancer Cause and Prevention Research; 93.395 – Cancer Treatment Research; 93.396 – Cancer Biology Research; 93.399 Cancer Control; 93.837 – Cardiovascular Diseases Research; 93.838 – Lung Diseases Research; 93.839 – Blood Diseases and Resources Research; 93.846 – Arthritis, Musculoskeletal and Skin Diseases Research; 93.847 – Diabetes, Digestive, and Kidney Diseases Extramural Research; 93.853 – Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.855 – Allergy, Immunology and Transplantation Research; 93.856 – Microbiology and Infectious Diseases Research; 93.859 – Biomedical Research and Research Training; 93.865 – Child Health and Human Development Extramural Research; 93.866 – Aging Research; 93.867 – Vision Research; 93.879 – Medical Library Assistance.

Funding Opportunity Number: PA-14-072

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2014-2 SBIR/STTR Program Descriptions and Research Topics for NIH. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-14-072.html>

PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parents SBIR [R43/R44])

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Small businesses.

CFDA Number: 93.061 -- Innovations in Applied Public Health Research; 93.084 -- Prevention of Disease, Disability, and Death by Infectious Diseases; 93.103 -- Food and Drug Administration_Research; 93.113 -- Environmental Health; 93.121 -- Oral Diseases and Disorders Research; 93.135 -- Centers for Research and Demonstration for Health Promotion and Disease Prevention; 93.136 -- Injury Prevention and Control Research and State and Community Based Programs; 93.172 -- Human Genome Research; 93.173 -- Research Related to Deafness and Communication Disorders; 93.213 -- Research and Training in Complementary

and Alternative Medicine; 93.233 -- National Center on Sleep Disorders Research; 93.242 -- Mental Health Research Grants; 93.262 -- Occupational Safety and Health Program; 93.273 -- Alcohol Research Programs; 93.279 -- Drug Abuse and Addiction Research Programs; 93.283 -- Centers for Disease Control and Prevention_ Investigations and Technical Assistance; 93.286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health; 93.307 -- Minority Health and Health Disparities Research; 93.350 -- National Center for Advancing Translational Sciences; 93.351 -- Research Infrastructure Programs; 93.361 -- Nursing Research; 93.393 -- Cancer Cause and Prevention Research; 93.394 -- Cancer Detection and Diagnosis Research; 93.395 -- Cancer Treatment Research; 93.396 -- Cancer Biology Research; 93.399 -- Cancer Control; 93.595 -- Welfare Reform Research, Evaluations and National Studies; 93.647 -- Social Services Research and Demonstration; 93.837 -- Cardiovascular Diseases Research; 93.838 -- Lung Diseases Research; 93.839 -- Blood Diseases and Resources Research; 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research; 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research; 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.855 -- Allergy, Immunology and Transplantation Research; 93.856 -- Microbiology and Infectious Diseases Research; 93.859 -- Biomedical Research and Research Training; 93.865 -- Child Health and Human Development Extramural Research; 93.866 -- Aging Research; 93.867 -- Vision Research; 93.879 -- Medical Library Assistance; 93.941 -- HIV Demonstration, Research, Public and Professional Education Projects; 93.977 -- Preventive Health Services_Sexually Transmitted Diseases Control Grants.

Funding Opportunity Number: PA-14-071

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2014-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, FDA and ACF. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PA-14-071.html>

NINDS Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows in MD-PhD Programs (F31)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education; Public and State controlled institutions

of higher education; For profit organizations other than small businesses; Hispanic-serving Institutions, .

CFDA Number: 93.853 – Extramural Research Programs in the Neurosciences and Neurological Disorders.

Funding Opportunity Number: PAR-13-127

The purpose of this individual predoctoral research training fellowship is to provide support for promising doctoral candidates who are enrolled in combined MD-PhD programs, who will be performing dissertation research and training in scientific health-related fields relevant to the mission of the National Institute of Neurological Disorders and Stroke. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-13-127.html>

Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public housing authorities/Indian housing authorities; Independent school districts); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Public and State controlled institutions of higher education.

CFDA Number: 93.273 – Alcohol Research Programs

Funding Opportunity Number: PA-14-198

The purpose of this FOA is to provide support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolizing pathways, their metabolites, cofactors, and interactions with synergizing biological pathways in the development of alcohol-induced diseases and end organ injuries. It is anticipated that this FOA will generate data that may lead to breakthroughs in our understanding of identifying key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive, long term alcohol consumption. In the future this knowledge may be critical in the diagnosis, treatment and management of vulnerable patient population debilitated by the vast array of alcohol-induced pathologies and enable clinicians to improve disease outcomes and, consequently, public health. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PA-14-198.html>

Outstanding Investigator Award (R35)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the

IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Public and State controlled institutions of higher education; Private institutions of higher education; Small businesses; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions.

CFDA Number: 93.393 – Cancer Cause and Prevention Research; 93.394 – Cancer Detection and Diagnosis Research; 93.395 – Cancer Treatment Research; 93.396 – Cancer Biology Research; 93.399 – Cancer Control.

Funding Opportunity Number: PAR-14-267

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to experienced investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit an application nominating an established Program Director/Principal Investigator (PD/PI) for a 7-year grant. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-14-267.html>

Blood Pressure Measurement Technologies for Low-Resource Settings in the US and India (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Estimated Total Program Funding: \$2,000,000

Eligibility: Private institutions of higher education; Special district governments; For profit organizations other than small businesses; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institution.

CFDA Number: 93.286 – Discovery and Applied Research for Technological Innovations to Improve Human Health

Funding Opportunity Number: RFA-EB-14-002

Hypertension diagnosis and management are critical needs in both the US and in India, and are opportune areas for technological innovation benefitting low-resource populations in both countries. The purpose of this FOA is to solicit research leading to the development of new blood-pressure measurement technologies for rapid, minimally intrusive, flexible monitoring and management of hypertension in underserved populations. These technologies must be noninvasive and minimally obtrusive. They should be usable in public areas for high-throughput screening, and/or be designed for individual use by untrained individuals in their own homes or regional healthcare settings. These new technologies would make substantial contributions to the improvement of hypertension diagnosis and management in both countries. A companion announcement has been released by the Indian government to support similar research by Indian investigators. All investigators funded by the US or India will share results at a yearly meeting and collaborations will be developed among investigators from both countries as the work progresses. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-14-002.html>

Gene-Environment Interplay in Substance Use Disorders (R03)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Independent school districts; Small businesses; Private institutions of higher education; Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations; Hispanic-serving Institutions.

CFDA Number: 93.273 – Alcohol Research Programs; 93.279 – Drug Abuse and Addiction Research Programs

Funding Opportunity Number: PA-11-237

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism seek to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates. Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field. Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and desistance of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-237.html>

Gene-Environment Interplay in Substance Use Disorders (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Public housing authorities/Indian housing authorities; Small businesses; For profit organizations other than small businesses; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations.

CFDA Number: 93.273 – Alcohol Research Programs; 93.279 – Drug Abuse and Addiction Research Programs

Funding Opportunity Number: PA-11-235

The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism seek to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates. Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field. Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and desistance of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-235.html>

Drug Abuse Prevention Intervention Research (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Independent school districts; Public and State controlled institutions of higher education; Private institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Faith-based or Community-based Organizations.

CFDA Number: 93.279 – Drug Abuse and Addiction Research Programs

Funding Opportunity Number: PA-11-311

The purpose of this FOA is to encourage Research Project Grant (R01) applications from institutions/organizations that propose to advance the science of drug abuse and drug-related HIV prevention through 1) the development of novel prevention approaches, 2) the testing of

novel and adapted prevention intervention approaches 3) the elucidation of processes associated with the selection, adoption, adaptation, implementation, sustainability, and financing of empirically validated interventions, and 4) the development of new methodologies suitable for the design and analysis of prevention research studies. Programs of research are intended to provide pathways toward the discovery of population-level approaches for the prevention of drug abuse and dependence, drug-related problems (such as mental health, interpersonal violence, criminal involvement, and productivity loss), and drug-related disorders (e.g., comorbid drug and psychiatric disorders; infections such as HIV, hepatitis B, and hepatitis C). **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-311.html>

Drug Abuse Prevention Intervention Research (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Private institutions of higher education; Faith-based or Community-based Organizations.

CFDA Number: 93.279 – Drug Abuse and Addiction Research Programs

Funding Opportunity Number: PA-11-312

The purpose of this FOA is to encourage Exploratory/Developmental (R21) applications from institutions/organizations that propose to advance the science of drug abuse and drug-related HIV prevention through 1) the development of novel prevention approaches, 2) the testing of novel and adapted prevention intervention approaches 3) the elucidation of processes associated with the selection, adoption, adaptation, implementation, sustainability, and financing of empirically validated interventions, and 4) the development of new methodologies suitable for the design and analysis of prevention research studies. Programs of research are intended to provide pathways toward the discovery of population-level approaches for the prevention of drug abuse and dependence, drug-related problems (such as mental health, interpersonal violence, criminal involvement, and productivity loss), and drug-related disorders (e.g., comorbid drug and psychiatric disorders; infections such as HIV, hepatitis B, and hepatitis C). **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-312.html>

Drug Abuse Prevention Intervention Research (R03)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Independent school districts; Public housing authorities/Indian housing authorities; For profit organizations other

than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Private institutions of higher education; Faith-based or Community-based Organizations.

CFDA Number: 93.279 – Drug Abuse and Addiction Research Programs

Funding Opportunity Number: PA-11-313

The purpose of this FOA is to encourage Small Research Grant (R03) applications from institutions/organizations that propose to advance the science of drug abuse and drug-related HIV prevention through 1) the development of novel prevention approaches, 2) the testing of novel and adapted prevention intervention approaches 3) the elucidation of processes associated with the selection, adoption, adaptation, implementation, sustainability, and financing of empirically validated interventions, and 4) the development of new methodologies suitable for the design and analysis of prevention research studies. Programs of research are intended to provide pathways toward the discovery of population-level approaches for the prevention of drug abuse and dependence, drug-related problems (e.g., mental health, interpersonal violence, criminal involvement, and productivity loss), and drug-related disorders (e.g., comorbid drug and psychiatric disorders; infections such as HIV, hepatitis B, and hepatitis C). **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-313.html>

Systems Science and Health in the Behavioral and Social Sciences (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: For profit organizations other than small businesses; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations.

CFDA Number: 93.113 -- Environmental Health; 93.121 -- Oral Diseases and Disorders Research; 93.242 -- Mental Health Research Grants; 93.273 -- Alcohol Research Programs; 93.286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health; 93.361 -- Nursing Research; 93.399 -- Cancer Control; 93.837 -- Cardiovascular Diseases Research; 93.859 -- Biomedical Research and Research Training; 93.865 -- Child Health and Human Development Extramural Research; 93.866 -- Aging Research

Funding Opportunity Number: PA-11-314

This Funding Opportunity Announcement (FOA) issued by the Office of Behavioral and Social Sciences Research (OBSSR) and the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of General Medical Sciences (NIGMS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) at the National Institutes of

Health, encourages Research Project Grant (R01) applications from institutions/organizations that propose to develop basic and applied projects utilizing systems science methodologies relevant to human behavioral and social sciences and health. This FOA is intended to encourage a broader scope of topics to be addressed with systems science methodologies, beyond those encouraged by existing open FOAs. Research projects applicable to this FOA are those that are either applied or basic in nature (including methodological development), have a human behavioral and/or social science focus, and feature systems science methodologies. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PA-11-314.html>

Systems Science and Health in the Behavioral and Social Sciences (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 7 2015

Eligibility: Small businesses; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Faith-based or Community-based Organizations.

CFDA Number: 93.113 -- Environmental Health; 93.121 -- Oral Diseases and Disorders Research; 93.242 -- Mental Health Research Grants; 93.273 -- Alcohol Research Programs; 93.286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health; 93.361 -- Nursing Research; 93.837 -- Cardiovascular Diseases Research; 93.859 -- Biomedical Research and Research Training; 93.865 -- Child Health and Human Development Extramural Research; 93.866 -- Aging Research.

Funding Opportunity Number: PA-11-315

This Funding Opportunity Announcement (FOA) issued by the Office of Behavioral and Social Sciences Research (OBSSR), and the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of General Medical Sciences (NIGMS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) at the National Institutes of Health, encourages Research Project Grant (R21) applications from institutions/organizations that propose to develop basic and applied projects utilizing systems science methodologies relevant to human behavioral and social sciences and health. This FOA is intended to encourage a broader scope of topics to be addressed with systems science methodologies, beyond those encouraged by existing open FOAs. Research projects applicable to this FOA are those that are either applied or basic in nature (including methodological development), have a human behavioral and/or social science focus, and feature

systems science methodologies. **For more information, go to:**
<http://grants.nih.gov/grants/guide/pa-files/PAR-11-315.html>

Basic Research in the Pathogenesis of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 8 2015

Eligibility: Public housing authorities/Indian housing authorities; Small businesses; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Faith-based or Community-based Organization

CFDA Number: 93.233 -- National Center on Sleep Disorders Research; 93.837 -- Cardiovascular Diseases Research; 93.838 -- Lung Diseases Research; 93.839 -- Blood Diseases and Resources Research

Funding Opportunity Number: RFA-HL-14-029

This Funding Opportunity Announcement (FOA) invites basic research project grant (R21) applications to investigate the fundamental mechanisms underlying the pathogenesis of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART). Investigations may be conducted on various primary cell types, biospecimens, computational models, and animal models, particularly those used for HIV research. The goal is to provide the critical basic science foundation and guide the design of new therapeutic approaches for HIV-related HLB conditions in adults and children. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-029.html>

Basic Research in the Pathogenesis of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 8 2015

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education ;Small businesses; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts

Private institutions of higher education); Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities

CFDA Number: 93.233 -- National Center on Sleep Disorders Research; 93.837 -- Cardiovascular Diseases Research; 93.838 -- Lung Diseases Research; 93.839 -- Blood Diseases and Resources Research

Funding Opportunity Number: RFA-HL-14-024

This Funding Opportunity Announcement (FOA) invites basic research project grant (R21) applications to investigate the fundamental mechanisms underlying the pathogenesis of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART). Investigations may be conducted on various primary cell types, biospecimens, computational models, and animal models, particularly those used for HIV research. The goal is to provide the critical basic science foundation and guide the design of new therapeutic approaches for HIV-related HLB conditions in adults and children. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-024.html>

Clinical Research in the Prevention, Diagnosis, and Treatment of HIV-Related heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 8 2015

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Independent school districts; Small businesses; Faith-based or Community-based Organizations.

CFDA Number: 93.233 -- National Center on Sleep Disorders Research; 93.837 -- Cardiovascular Diseases Research; 93.838 -- Lung Diseases Research; 93.839 -- Blood Diseases and Resources Research

Funding Opportunity Number: RFA-HL-14-023

This Funding Opportunity Announcement (FOA) invites clinical research project grant (R01) applications on the prevention, diagnosis, and treatment of HIV-related heart, lung, and/or blood (HLB) diseases in adults and children. Proposed projects may utilize various approaches such as observational studies; quasi-experimental designs; and single-center, pilot trials. Whenever possible, investigators are strongly encouraged to leverage existing infrastructure such as clinical cohorts, biological specimens and imaging banks. The goal of this FOA is to address major scientific gaps in characterizing, preventing, diagnosing, or treating HIV-related HLB diseases and foster multi-disciplinary collaborations among investigators. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-023.html>

Biomarkers of Alzheimers Disease in Down Syndrome (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 12 2015

Estimated Total Program Funding: \$5,000,000

Eligibility: For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Small businesses; Independent school districts; Private institutions of higher education; Faith-based or Community-based Organizations.

CFDA Number: 93.865 -- Child Health and Human Development Extramural Research; 93.866 -- Aging Research

Funding Opportunity Number: RFA-AG-15-011

The goal of this funding opportunity announcement is to enable the identification of the longitudinal progression of Alzheimer's disease in adults with Down Syndrome using clinical, cognitive, imaging, genetic and biochemical biomarkers. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-011.html>

NIMHD Academic Research Enhancement Award: Enhancing Health Disparities Research at Undergraduate Institutions (R15)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 12 2015

Estimated Total Program Funding: \$5,000,000

Eligibility: Small businesses; Private institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; For profit organizations other than small businesses; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations.

CFDA Number: 93.307 – Minority Health and Health Disparities Research

Funding Opportunity Number: RFA-MD-15-002

The NIMHD encourages institutions that are eligible to apply for support through the NIH Academic Research Enhancement Awards (AREA) program to submit applications for innovative research projects focused on minority health and health disparities. Awards are intended to support small-scale projects proposed by faculty members at eligible institutions to expose students to meritorious research and to strengthen the research environment of participating institutions. This initiative also seeks to stimulate interest in health disparities

research careers among undergraduate students through hands-on participation in original research. **For more information, go to:**
<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-15-002.html>

NHLBI Systems Biology Collaborations (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 13 2015

Eligibility: Private institutions of higher education; Independent school districts
Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; For profit organizations other than small businesses; Faith-based or Community-based Organizations.

CFDA Number: 93.837 -- Cardiovascular Diseases Research; 93.838 -- Lung Diseases Research; 93.839 -- Blood Diseases and Resources Research

Funding Opportunity Number: PAR -12-138

This FOA issued by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, encourages Research Project Grant (R01) applications from institutions/organizations that propose collaborative systems biology research projects by multi-disciplinary teams to advance our understanding of normal physiology and perturbations associated with heart, lung, blood, and sleep (HLBS) diseases and disorders. Multi-disciplinary expertise across experimental and computational domains is required, and the multi-PI mechanism is allowed, as integration across these domains is a critical element of the proposed research plan. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-12-138.html>

(Re)Building a Kidney: Cells to Organ (UH2/UH3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 14 2015

Eligibility: Private institutions of higher education; Public and State controlled institutions of higher education; Small businesses; Independent school districts; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations.

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-010

This Funding Opportunity Announcement (FOA) invites new research project applications to participate in the NIDDK (Re)Building a Kidney Consortium. The projects will be part of a research network focused on the expansion of tools, resources, and knowledge that will guide

studies on the in vivo regeneration of functional nephrons or in vitro generation of nephrons for kidney transplant. Funds will be made available through the UH2/UH3 cooperative agreement award mechanism. The initial UH2 phase will support milestone-driven projects that will inform strategies for the enhancement of endogenous regenerative repair processes and generation of cell types important for the development of functional nephrons. UH2 projects that have met their scientific milestones will be eligible for transition to the second UH3 phase after NIH administrative review. The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. UH3 phase will support milestone-driven projects. It is anticipated that relevant projects will be integrated as appropriate to further synergistic interactions and collaborations. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-010.html>

(Re)Building a Kidney: Cells to Organ (UH2/UH3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 14 2015

Eligibility: Public and State controlled institutions of higher education; Private institutions of higher education; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Independent school districts; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations.

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-009

This Funding Opportunity Announcement (FOA) is a new initiative to invite applications to participate in the Kidney Consortium as the Coordinating Center. The consortium Coordinating Center will manage activities of the consortium including research opportunities (e.g., the Opportunity Pool program), and facilitate communication of research results, data, and methods within the consortium and with the community. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-009.html>

Peer Reviewed Alzheimer's Convergence Science Research Award

Granting Agency: Dept. of the Army -- USAMRAA

Current Closing Date for Applications: Jan, 14 2015

Expected Number of Awards: 4

Estimated Total Program Funding: \$2,600,000

Eligibility: Unrestricted

CFDA Number: 12.420 – Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-PRARP-CSRA

The PRARP Convergence Science Research Award mechanism was first offered in FY12. Since then, 72 Convergence Science Research Award applications have been received, and 12 have

been recommended for funding. The intent of the FY14 CSRA is to support efforts to generate research resources and tools, or novel research efforts for professionals and practitioners in health sciences related to the PRARP's mission. The research impact is intended to benefit the military community, while meeting a public purpose for the benefit of the civilian community. Overarching Challenges: This CSRA funding opportunity requires applications to address one or more of the following PRARP Overarching Challenges: Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD for military Veterans/other individuals affected by TBI. Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD for military Veterans/other individuals affected by TBI. Diagnostic Technologies, Tests, Interventions, or Devices: The need for technologies, tests, interventions, or devices with the potential to diagnose AD at its earliest stages. Focus Areas: In addition to addressing one or more of the specified Overarching Challenges, applications must also address at least one of the following FY14 PRARP Focus Areas in support of the Overarching Challenges. An application that proposes research outside of these Focus Areas is acceptable, as long as the applicant provides a strong rationale: Genomics/Proteomics/Bioinformatics: Studies or technologies (e.g., genetic, proteomic, and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD. In addition, relevant technologies or tests may be considered under this Focus Area. Pathology of Tau: Novel research and technologies dedicated to unraveling the basic pathological mechanisms of Tau associated with TBI and AD. New! Roles of non-neuronal cells in TBI/AD pathogenesis: Technologies, tests, studies, or devices that will examine the roles of astrocytes (or other non-neuronal cells) in AD neurodegeneration due to TBI. While the CSRA mechanism can be used to support clinical research, the following is specifically discouraged under the FY14 PRARP: Pharmacologic Interventions: Clinical or Basic research requiring investigational or FDA-approved drugs or medicines. Drug Discovery and Development: Clinical or Basic research directly leading to the development of investigational medicines, drugs, or agents.

DoD Peer Reviewed Alzheimer's Quality of Life Research Award

Granting Agency: Dept. of the Army -- USAMRAA

Current Closing Date for Applications: Jan, 14 2015

Expected Number of Awards: 4

Estimated Total Program Funding: \$2,600,000

Eligibility: Unrestricted

CFDA Number: 12.420 – Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-PRARP-QUAL

The intent of the research funded through the FY14 Quality of Life Research Award (QUAL) is to reduce the burden on caregivers and individuals affected by the common symptoms of both TBI and AD, especially in the military community. Overarching Challenges: This QUAL funding opportunity requires applications to address one or both of the following PRARP Overarching Challenges: Quality of Life: The need for technologies, tests, interventions, epidemiological studies, or devices with the potential to benefit individuals suffering from common symptoms of TBI and AD. Caregiver Burden: The need for technologies, tests, interventions, epidemiological

studies, or devices with the potential to reduce caregiver burden for individuals affected by the common symptoms of TBI and AD. Focus Areas: In addition to addressing one or both of the specified Overarching Challenges, applications must also address at least one of the following FY14 PRARP Focus Areas in support of the specified Overarching Challenge(s). An application that proposes research outside of these Focus Areas is acceptable, as long as the applicant provides a strong rationale: Care Interventions and Quality of Life: Research intended to stabilize or improve the quality of life of those affected by the common symptoms of TBI and AD. Examples of research in this focus area include: Cognitive Training Interventions Studies of Health and Wellness Behavioral Interventions Neuropsychological Interventions Caregiver support: Research intended to reduce the burden of care on the caregiver for individuals affected by the common symptoms of TBI and AD. Examples of research in this focus area include: Caregiver Training Home Based Support Behavioral Interventions Relationship Interventions While the QUAL mechanism can be used to support clinical research, the following is specifically discouraged under the FY14 PRARP: Pharmacologic Interventions: Clinical or Basic research requiring investigational or FDA-approved drugs or medicines. Drug Discovery and Development: Clinical or Basic research directly leading to the development of investigational medicines, drugs or agents.

DoD Peer Reviewed Alzheimer's Quality of Life Research Award

Granting Agency: Dept. of the Army -- USAMRAA

Current Closing Date for Applications: Jan, 14 2015

Expected Number of Awards: 1

Estimated Total Program Funding: \$5,500,000

Eligibility: Unrestricted

CFDA Number: 12.420 – Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-PRARP-MRFA

The intent of the FY14 Military Risk Factors Research Award (MRFA) is to facilitate high-impact, systematic, population-based research investigating the association between TBI and the subsequent development of AD. Applications should describe how the association of TBI and subsequent AD will be characterized. Applications should also describe how the proposed study will work with well-defined, already identified study cohorts. Applications should carefully consider how their studies will characterize the cognitive and behavioral symptoms that result in functional impairments in the proposed cohort. Studies that use combinations of measures (e.g., neuropsychological assessments, imaging, genomics, and cerebral spinal fluid) are encouraged. Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged. Important Note: Applications must detail and demonstrate expedited access to a well-defined, already identified study cohort. Preliminary data that supports how the cohort will be used in the study is also required. The preliminary data must strongly support the proposed research hypothesis (or hypotheses). Refer to the Review Criteria in this Program Announcement/ Funding Opportunity for details. Overarching Challenge: This MRFA funding opportunity requires applications to address the following PRARP Overarching Challenge: Paucity of Clinical Studies: The paucity of clinical studies and other research resources to examine the interrelationship between TBI and subsequent AD for military

Veterans/other individuals affected by TBI. Focus Areas: In addition to addressing the Overarching Challenge, applications must also address at least one of the following FY14 PRARP Focus Areas in support of the Overarching Challenge. An application that proposes research outside of these Focus Areas is acceptable, as long as the applicant provides a strong rationale: Genomics/Proteomics/Bioinformatics: Studies or technologies (e.g., genetic, proteomic and epigenetic strategies) intended to characterize neurological change associated with TBI and subsequent AD. In addition to studies, relevant technologies or tests may be considered under this focus area. Imaging: Development and application of anatomic and molecular imaging strategies to characterize neurological changes associated with TBI and subsequent AD While the MRFA mechanism can be used to support clinical research, the following is specifically discouraged under the FY14 PRARP: Pharmacologic Interventions: Clinical or Basic research requiring investigational or FDA-approved drugs or medicines. Drug Discovery and Development: Clinical or Basic research directly leading to the development of investigational medicines, drugs, or agents.

Epigenetic Analyses of Aging as a Risk Factor for Multiple Chronic Conditions (U34)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 15 2015

Expected Number of Awards: 2

Estimated Total Program Funding: \$800,000

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Independent school districts; Small businesses; Faith-based or Community-based Organizations.

CFDA Number: 93.866 -- Aging Research

Funding Opportunity Number: RFA-AG-15-004

The emergent field of geroscience seeks to relate the biology of aging to the development of chronic diseases and the onset of degenerative conditions which are prevalent in the older segment of human populations. It is generally accepted that age is the major risk factor for most chronic diseases and degenerative conditions in adults. Thus, a critical question in geroscience is to identify components in the biology of aging that are the underlying risk for multiple chronic diseases and degenerative conditions. Therefore, this FOA will support planning grants to circumscribe the scope of this question and suggest ways to answer it experimentally. The focus will be on epigenetics underlying aging as a risk factor for age-related diseases and degenerative conditions in humans. Mortality and age-related mortality are outside the scope of this FOA.

Studies using model organisms are outside the scope of this FOA. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-004.html>

Analyses of Datasets on Older Populations with High Prevalence of Mobility Disability to Develop Clinically Meaningful Diagnostic Cut-Points for Low Muscle Mass and/or Low Muscle Strength (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 15 2015

Expected Number of Awards: 1

Estimated Total Program Funding: \$750,000

Eligibility: Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Independent school districts; Special district governments; Small businesses; Private institutions of higher education; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.866 -- Aging Research

Funding Opportunity Number: RFA-AG-15-013

This initiative invites applications for support of analyses of existing data (or data whose collection will be completed by one year from the date of this FOA) from older populations with high prevalence of mobility disability, low muscle mass, and low muscle strength (weakness). Interventions targeted at low muscle mass and/or weakness may prevent or reduce mobility disability in some older persons. To assess the efficacy of such interventions against mobility disability, there is a need to test them in persons in whom muscle mass and/or strength are (or will be) sufficiently low to be likely contributors to disability. Thus there is a need for evidence-based diagnostic cut-points to define target populations for treatments. Applications submitted in response to this FOA should support development and evaluation of diagnostic cut-points based on analyses of relations of mobility disability to muscle mass and strength. These analyses should extend and expand upon analyses to date on this topic, which have identified and proposed cut-points for low muscle mass and weakness. Studies supported through this FOA should clarify relations between muscle mass and strength, impaired physical function, and mobility disability, and their implications for setting diagnostic cut-points, through analyses of data from populations with substantially more individuals with mobility disability than were included in previous analyses. Applicants are encouraged to consider combining datasets from multiple populations that contain information on all of the following: at least one objective measure of muscle mass at the same anatomic site(s) common to all included studies, at least one direct measure of muscle strength common to included data sets, gait speed, and self-reported mobility status in populations of older adults. Analyses of relations to other measures of strength, muscle power, and physical performance (e.g., Short Physical Performance Battery), and mobility disability are encouraged. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-013.html>

Clinical and Transnational Science Award (U54)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 15 2015

Expected Number of Awards: 21

Estimated Total Program Funding: \$110,000,000

Eligibility: Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; The CTSA application may include domestic institutions of higher education, universities, academic health centers, or non-profit research organizations other than institutions of higher education that conduct clinical and translational research; however, a graduate school accredited to award higher degrees in clinical or translational science must be included (e.g., M.S. or Ph.D. in topics such as Clinical Research, Public Health, Pharmacology, Nursing, Informatics, Health Economics, or Epidemiology. Partnerships are encouraged among various disciplines including medicine, dentistry, nursing, pharmacy, osteopathy, public health, engineering and others).

CFDA Number: 93.350 -- National Center for Advancing Translational Sciences

Funding Opportunity Number: RFA-TR-14-009

The purpose of this funding opportunity announcement (FOA) is to invite applications to participate in the Clinical and Translational Science Award (CTSA) program which supports high quality translational and clinical research locally, regionally, and nationally, and fosters innovation in methods, training, and career development. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-14-009.html>

Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 16 2015

Eligibility: Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Small businesses; Faith-based or Community-based Organizations; Public housing authorities/Indian housing authorities

CFDA Number: 93.103 -- Food and Drug Administration_Research; 93.121 -- Oral Diseases and Disorders Research; 93.173 -- Research Related to Deafness and Communication Disorders; 93.242 -- Mental Health Research Grants; 93.273 -- Alcohol Research Programs; 93.279 -- Drug Abuse and Addiction Research Programs; 93.350 -- National Center for Advancing Translational Sciences; 93.853 -- Extramural Research Programs in the Neurosciences and Neurological

Disorders; 93.865 -- Child Health and Human Development Extramural Research; 93.866 -- Aging Research; 93.867 -- Vision Research

Funding Opportunity Number: PAR-14-211

The National Center for Advancing Translational Sciences (NCATS) seeks to expand the therapeutics discovery program piloted in 2012, to explore new therapeutic uses for proprietary drug candidates (Agents) across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Agents from pharmaceutical company partners. A strong application will be supported by scientific evidence that modulation of the Agents target will have a positive impact on the disease/condition. PAR-14-213 encourages X02 pre-applications for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules. The X02 pre-application is the first step in the application process for PAR-14-212, PAR-14-210, and PAR-14-211; applicants must read all of the companion FOAs. The X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious will be notified of the opportunity to submit a UH3 application under this FOA or a UH2/UH3 under PAR-14-212 or a UH2/UH3 application under PAR-14-210 in the case of a pediatric indication. The UH3 will support milestone-driven Phase 2a trials to demonstrate that the Agent, made available for this program by the pharmaceutical partners, modulates the target and has the potential to yield the desired clinical outcome in the proposed disease population. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-14-211.html>

Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 16 2015

Eligibility: Small businesses; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations

CFDA Number: 93.103 -- Food and Drug Administration_Research; 93.121 -- Oral Diseases and Disorders Research; 93.173 -- Research Related to Deafness and Communication Disorders; 93.242 -- Mental Health Research Grants; 93.273 -- Alcohol Research Programs; 93.279 -- Drug Abuse and Addiction Research Programs; 93.350 -- National Center for Advancing Translational Sciences; 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.865 -- Child Health and Human Development Extramural Research; 93.866 -- Aging Research; 93.867 -- Vision Research

Funding Opportunity Number: PAR-14-212

The National Center for Advancing Translational Sciences (NCATS) seeks to expand the therapeutics discovery program piloted in 2012 to explore new therapeutic uses for proprietary drug candidates (Agents) across a broad range of human diseases. This innovative program

allows investigators to propose new therapeutic uses for Agents from pharmaceutical company partners. A strong application will be supported by scientific evidence that modulation of the Agents target will have a positive impact on the disease/condition. PAR-14-213 encourages X02 pre-applications for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules. The X02 pre-application is the first step in the application process for PAR-14-212, PAR-14-210, and PAR-14-211; applicants must read all of the companion FOAs. The X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious will be notified of the opportunity to submit a UH2/UH3 application under this FOA or a UH3 under PAR-14-211 or a UH2/UH3 application under PAR-14-210 in the case of a pediatric indication. The UH2/UH3 is a two stage application. 1. The UH2 (Stage 1) may be used to support milestone-driven preclinical studies to verify target engagement in a disease model and/or Phase 1b clinical trials using the selected Agent in its existing formulation/route of administration to identify the dose or exposure of the Agent in the proposed patient group, and inform patient selection. Support for the UH2 may be requested for a period that may vary from six months up to one year. UH2 projects that have met the scientific milestones and feasibility requirements will be eligible for rapid transition to the second UH3 stage after NIH administrative review. 2. The UH3 (Stage 2) will support milestone-driven Phase 2a trials to demonstrate that the Agent, made available for this program by the pharmaceutical partners, modulates the target and has the potential to yield the desired clinical outcome in the proposed disease population. The project period for the UH3 stage is up to two years. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-14-212.html>

Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 16 2015

Eligibility: Small businesses; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations

CFDA Number: 93.103 -- Food and Drug Administration_Research; 93.121 -- Oral Diseases and Disorders Research; 93.173 -- Research Related to Deafness and Communication Disorders; 93.242 -- Mental Health Research Grants; 93.273 -- Alcohol Research Programs; 93.279 -- Drug Abuse and Addiction Research Programs; 93.350 -- National Center for Advancing Translational Sciences; 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.865 -- Child Health and Human Development Extramural Research; 93.866 -- Aging Research; 93.867 -- Vision Research

Funding Opportunity Number: PAR-14-210

The National Center for Advancing Translational Sciences (NCATS) seeks to expand the therapeutics discovery program piloted in 2012 to explore new therapeutic uses for proprietary

drug candidates (Agents) across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Agents from pharmaceutical company partners. A strong application will be supported by scientific evidence that modulation of the Agents target will have a positive impact on the disease/condition. PAR-14-213 encourages X02 pre-applications for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules. The X02 pre-application is the first step in the application process for PAR-14-212, PAR-14-210, and PAR-14-211; applicants must read all of the companion FOAs. The X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious will be notified of the opportunity to submit a UH2/UH3 application under this FOA or a UH3 under PAR-14-211 or a UH2/UH3 application under PAR-14-210 in the case of a pediatric indication. The UH2/UH3 is a two stage application. 1. The UH2 (Stage 1) may be used to support milestone-driven preclinical studies to verify target engagement in a disease model and/or Phase 1b clinical trials using the selected Agent in its existing formulation/route of administration to identify the dose or exposure of the Agent in the proposed patient group, and inform patient selection. Support for the UH2 may be requested for a period that may vary from six months up to one year. UH2 projects that have met the scientific milestones and feasibility requirements will be eligible for rapid transition to the second UH3 stage after NIH administrative review. 2. The UH3 (Stage 2) will support milestone-driven Phase 2a trials to demonstrate that the Agent, made available for this program by the pharmaceutical partners, modulates the target and has the potential to yield the desired clinical outcome in the proposed disease population. The project period for the UH3 stage is up to two years. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-14-210.html>

System-Level Health Services and Policy Research on Health Disparities (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 20 2015

Expected Number of Awards: 6

Estimated Total Program Funding: \$3,000,000

Eligibility: Independent school districts; Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations

CFDA Number: 93.307 -- Minority Health and Health Disparities Research47.075 -- Social, Behavioral, and Economic Sciences

Funding Opportunity Number: RFA-MD-15-001

The purpose of this Funding Opportunity Announcement (FOA) is to solicit innovative system-level health services and policy research that can directly and demonstrably contribute to the elimination of health disparities. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-15-001.html>

DoD Orthotics and Prosthetics Outcomes Research Award

Granting Agency: Dept. of the Army - USAMRAA

Current Closing Date for Applications: Jan, 20 2015

Expected Number of Awards: 6

Estimated Total Program Funding: \$8,900,000

Eligibility: Unrestricted

CFDA Number: 12.420 -- Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-OPORP-OPORA

The OPORP Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding of and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies. Studies are sought that:

- Compare different patient care approaches.
- Include patient-centric outcome assessments.
- Have the potential to generate new knowledge that can be developed into new clinical practice guidelines, and/or new prescription algorithms for prosthetic and orthotic devices.
- Have the potential to develop new technology for improved prosthetic and orthotic devices, therefore improving patient outcomes.
- Provide information on quality of life, reintegration, and/or return to duty/return to work as it pertains to those patients who use a prosthetic or orthotic device due to limb trauma.

All applications must demonstrate direct relevance to Service Members and Veterans with traumatic extremity injury and/or amputation using prosthetics and orthotic devices. Examples of studies that are appropriate for submission to the FY14 OPORA include, but are not limited to, examination of the long-term functional and patient-centered outcomes associated with:

- The specific time points in the course of patient treatment where prosthetic and orthotic intervention is the most effective.
- Different treatment algorithms to determine the most appropriate prosthetic/orthotic device.
- The effect of different orthotic and/or prosthetic devices on achievement of maximal functional ability.
- Development of outcomes evaluating the prevention of secondary adverse consequences of prosthetic and orthotic device use, including but not limited to falls, skin breakdown, loss of balance.
- Improvement of current prosthetic and orthotic materials and techniques to improve quality of life and health outcomes for patients with limb trauma or limb loss.
- Development of new materials and technologies for use in orthotics and prosthetics to improve quality of life and health outcomes for patients with limb trauma or limb loss.
- Application of specific rehabilitation interventions to accelerate the time, course, or extent of functional outcomes in Service Members and Veterans using prosthetic and orthotic devices.

Studies may also be proposed that consider outcome factors related to health care delivery and clinical decision-making such as cost, accessibility, adoption of medical policy, and

patient preferences. Studies should have a clinical focus and may include methodologies and designs such as surveys, retrospective data analyses, simulation modeling, longitudinal observation, cross sectional observation, case control, or qualitative research study designs. Animal studies are not allowed under this award mechanism. Research Scope: Research proposed under the FY14 OPOA may include small- to large-scale projects and be at different stages of idea and research development including efficacy studies, effective comparison studies, human use, observational studies, and clinical trials. Two different funding levels, based on the scope of the research, are available under this Program Announcement/Funding Opportunity. Clinical research and clinical trials will be considered for both funding levels. It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the proposed research project. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: • Funding Level 1: Research that is already supported by preliminary data and has the potential to make significant advancements toward clinical translation. • Funding Level 2: Advanced translational studies that have the potential for near-term clinical investigation.

Interpreting Variation in Human Non-Coding Genomic Regions Using Computation Approaches and Experimental Assessment (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 21 2015

Eligibility: Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Private institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Independent school districts; Faith-based or Community-based Organizations

CFDA Number: 93.172 -- Human Genome Research; 93.279 -- Drug Abuse and Addiction Research Programs; 93.394 -- Cancer Detection and Diagnosis Research; 93.395 -- Cancer Treatment Research; 93.396 -- Cancer Biology Research; 93.399 -- Cancer Control

Funding Opportunity Number: RFA-HG-13-013

This Funding Opportunity Announcement (FOA) solicits applications to develop highly innovative computational approaches for interpreting sequence variants in the non-protein-coding regions of the human genome. The goal is to develop methods that analyze whole-genome sequence data by integrating data sets, such as ones on genome function, phenotypes, patterns of variation, and other features, to identify or substantially narrow the set of variants that are candidates for affecting organismal function leading to disease risk or other traits. The accuracy of the computational approaches developed should be assessed using experimental data.

For more information, go to:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-13-013.html>

Definition of Resilience and Pre-Symptomatic Disease in Lung Health and Disease (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 21 2015

Eligibility: Public and State controlled institutions of higher education; For profit organizations other than small businesses; Independent school districts; Private institutions of higher education; Small businesses; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.838 -- Lung Diseases Research

Funding Opportunity Number: RFA-HL-15-024

The purpose of this FOA is to invite applications that will seek to prospectively define and/or validate pulmonary or immune system attributes associated with pre-symptomatic disease states or resilience, with the goal of informing the development of primary prevention strategies for chronic lung diseases. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-024.html>

Pre-Symptomatic Profiles of Chronic Lung Disease(s) from Retrospective Cohorts (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 21 2015

Expected Number of Awards: 6

Estimated Total Program Funding: \$2,640,000

Eligibility: Private institutions of higher education; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; For profit organizations other than small businesses); Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations

CFDA Number: 93.838 -- Lung Diseases Research

Funding Opportunity Number: RFA-HL-15-025

Research applications are requested that stimulate focused secondary analyses of existing clinical research datasets to test innovative hypotheses about the epidemiology of incident chronic lung disease(s). Novel analyses of existing data will generate clinical and/or biological phenotypes of the pre-symptomatic stages of chronic lung disease(s) and serve as preliminary data for subsequent research applications on primary prevention. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-025.html>

DoD PH/TBI Investigational Treatments for TBI and PTSD Clinical Trial Award

Granting Agency: Dept. of the Army -- USAMRAA

Current Closing Date for Applications: Jan, 23 2015

Expected Number of Awards: 2

Estimated Total Program Funding: \$5,000,000

Eligibility: Unrestricted

CFDA Number: 12.420 -- Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-PHTBIRP-ITTPCTA15-504

The intent of the FY14 PH/TBIRP Investigational Treatments for TBI and PTSD Clinical Trial Award (ITTPCTA) is to address Section 704 of the National Defense Authorization Act for Fiscal Year 2014, which directs a pilot program and establishment of a process for randomized placebo-controlled clinical trials of investigational treatments (including diagnostic testing) of TBI and PTSD received by members of the Armed Forces in health care facilities other than military treatment facilities.

DoD PH/TBI Community Partners in Mental Health Research Award

Granting Agency: Dept. of the Army -- USAMRAA

Current Closing Date for Applications: Jan, 23 2015

Expected Number of Awards: 2

Estimated Total Program Funding: \$5,000,000

Eligibility: Unrestricted

CFDA Number: 12.420 -- Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-PHTBIRP-CPMHRA

The intent of the FY14 PH/TBIRP Community Partners in Mental Health Research Award (CPMHRA) is to address Section 706 by supporting research on the causes, development, and innovative treatment of mental health, substance use disorders, TBI, and suicide prevention in members of the National Guard and Reserves, their family members, and their caregivers. The focus of the CPMHRA is on research only; proposed projects should NOT include other treatment, education, and outreach efforts. Research projects should be carried out by or in collaboration with community partners. Community partners as referenced in Section 706 are private non-profit organizations or institutions that engage in (1) research on the causes, development, and innovative treatment; (2) identifying and disseminating evidence-based treatments; and/or (3) outreach and education for mental health, substance use disorders, TBI, and suicide prevention in members of the National Guard and Reserves, their family members, and their caregivers.

Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 23 2015

Estimated Total Program Funding: \$1,000,000

Eligibility: Small businesses

CFDA Number: 93.307 -- Minority Health and Health Disparities Research

Funding Opportunity Number: RFA-MD-15-003

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes. Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-15-003.html>

Regional Consortia for High Resolution Cryoelectron Microscopy (U24)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 27 2015

Eligibility: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Private institutions of higher education; Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; Small businesses; Faith-based or Community-based Organizations

CFDA Number: 93.859 -- Biomedical Research and Research Training

Funding Opportunity Number: RFA-GM-16-001

The purpose of this Funding Opportunity Announcement (FOA) is to provide regional access for cryoelectron microscopy (cryoEM) laboratories to state-of-the-art data collection capabilities.

NIGMS will support consortia of established and early stage investigator laboratories whose research has an established specialization in and dependence on cryoEM. These laboratories will coordinate with each other to share facilities and resources for direct electron detection.

Consortia will consist of a host institution which already has a modern high-performing cryoEM installation and proven capabilities for high-resolution data collection, partnered with regional participating institutions. A consortium will support surplus capacity for cryoEM data collection (infrastructure and services) at the host institution and make it available as a resource for the participating regional institutions. Projects will support access for cryoEM laboratories at participating institutions to resources and services at host sites. Projects will (a) contribute to the fixed costs of maintaining the host facility and extend services in proportion to the resources

dedicated to the regional users and (b) support access to the facility by the regional laboratories. The host institution need not already have an electron detector; this FOA can help fund acquisition of direct detection equipment. Support is limited to enabling the participating cryoEM laboratories to collect data and perform the initial stages of processing raw images, and does not include other research activities. Consortia will consist of a minimum of 3-5 institutions; award budgets will depend on the number and data collection needs of the regional participating cryoEM laboratories. This initiative is not intended to support service centers of the traditional type in which the host laboratory performs the cryoEM analysis for non-specialist collaborators. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-16-001.html>

Innovations for Healthy Living- Improving Minority Health and Eliminating Health Disparities (R43)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 27 2015

Estimated Total Program Funding: \$600,000

Eligibility: Small Businesses

CFDA Number: 93.307 -- Minority Health and Health Disparities Research

Funding Opportunity Number: RFA-MD-15-004

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes. Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-15-004.html>

Interdisciplinary Complementary and Integrative Health Clinical Research Training Award (T90/R90)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 28 2015

Eligibility: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; ; Faith-based or Community-based Organizations

CFDA Number: 93.213 -- Research and Training in Complementary and Alternative Medicine

Funding Opportunity Number: PAR-13-065

The National Center for Complementary and Alternative Medicine (NCCAM) is establishing this clinical research training program aimed at improving the capacity of the integrative health field to carry out rigorous research. This Funding Opportunity Announcement (FOA) will fund coherent and unified partnerships between institutions with research intensive environments (e.g., T32 and CTSA institutions) and institutions with curricula focused on clinical training of practitioners in complementary modalities and disciplines that also have faculty with a substantial interest in rigorous clinical research. The program will support mentored research training and hands-on experiences in clinical research, as well as trainee-focused developmental efforts including didactic activities in clinical research methodology, integrative health, and trainee-initiated pilot clinical research projects within NCCAM's research priority areas. The funded institutional programs are expected to generate a cadre of research clinicians who are able to participate fully in multi-disciplinary teams engaged in complementary and integrative health research. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-065.html>

Aging and Neuromuscular Junctions (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 29 2015

Expected Number of Awards: 6

Estimated Total Program Funding: \$2,500,000

Eligibility: For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Public and State controlled institutions of higher education; Private institutions of higher education

CFDA Number: 93.866 -- Aging Research

Funding Opportunity Number: RFA-AG-15-008

The purpose of this FOA is to encourage cross-disciplinary research to investigate the mechanisms underlying age-related declines in neuromuscular junctions (NMJs) as a functional unit of nerve and muscle, and explore potential avenues for maintaining the NMJs during aging or reversing the age-dependent loss in function of the NMJs using model organisms.

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-008.html>

Immune and Inflammatory Mechanisms in Alzheimer's Disease (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 29 2015

Eligibility: Small businesses; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Independent school districts; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Faith-based or Community-based Organization

CFDA Number: 93.866 -- Aging Research

Funding Opportunity Number: RFA-AG-15-018

The goal of this FOA is to establish the role of the brain innate immune system, the systemic immune system, and the crosstalk and changes with age between the two in the development and progression of Alzheimers disease. An interdisciplinary and integrative research approach to identify the cell networks and mediators of the brain and systemic immune and inflammatory systems is expected to give greater insight into the etiological mechanisms underlying Alzheimers disease. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-018.html>

DoD Breast Cancer Breakthrough Award Levels 3 and 4

Granting Agency: Dept. of the Army -- USAMRAA

Current Closing Date for Applications: Jan, 29 2015

Expected Number of Awards: 7

Estimated Total Program Funding: \$20,000,000

Eligibility: Unrestricted

CFDA Number: 12.420 -- Military Medical Research and Development

Funding Opportunity Number: W81XWH-14-BCRP-BREAKTHROUGH2-FL34

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. Funding Levels 1 and 2 are available under a different Program Announcement (W81XWH-14-BCRP-BREAKTHROUGH2_FL12). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: • Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply. • Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects. Note: An invited oral presentation to the BCRP Integration Panel (IP) is a requirement for application review of Funding Level 4 projects, as described in Section II.C., Application Submission Content and Forms. Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. The Partnering PI Option is structured to accommodate two PIs, called the Initiating PI and the Partnering PI, each of whom will each receive a separate award. The Initiating and Partnering PIs have different submission

requirements; however, both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. New collaborations are encouraged, but not required. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly addressing distinct research questions.

Planning Grants for Dental, Oral and Craniofacial Tissue Regeneration Consortium Resource Centers (R34)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 29 2015

Estimated Total Program Funding: \$1,800,000

Eligibility: Public and State controlled institutions of higher education; Private institutions of higher education; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.121 -- Oral Diseases and Disorders Research

Funding Opportunity Number: RFA-DE-15-005

This Funding Opportunity Announcement (FOA) invites Planning Grant applications to articulate a vision, roadmap, organizational structure and operational procedures for establishing Resource Centers (RCs). These planning grants are intended to enable the institutions to develop the necessary partnerships and infrastructure needed to be competitive for establishing successful RCs. It is envisioned that the RCs will provide technical support and research capacity for a future Dental Oral and Craniofacial Tissue Regeneration Consortium (DOCTRC). **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-15-005.html>

Countermeasures Against Chemical Threats (CounterAct) Exploratory/Developmental Projects in Translational Research (R21)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 30 2015

Eligibility: Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public

housing authorities/Indian housing authorities; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education); Faith-based or Community-based Organizations

CFDA Number: 93.113 -- Environmental Health; 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research; 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.859 -- Biomedical Research and Research Training; 93.865 -- Child Health and Human Development Extramural Research; 93.867 -- Vision Research

Funding Opportunity Number: PAR-13-005

This Funding Opportunity Announcement (FOA) encourages applications for exploratory/developmental translational research on therapeutics for reducing mortality and morbidity caused by acute exposures to chemical threat agents. Chemical threats include chemical warfare nerve agents such as sarin and VX, toxic industrial chemicals such as cyanide and phosgene, and toxic agricultural chemicals such as parathion and sodium fluoroacetate. Projects supported by this FOA are expected to generate preliminary preclinical, screening and efficacy data that would enable the development of competitive applications for more extensive support from the NIH CounterACT program (see www.ninds.nih.gov/counteract for a description) and other related translational research programs. **For more information, go to:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-005.html>

Developmental Origins of Health and Disease (DOHaD): Epigenetic Modification in Gametogenesis and Transgenerational Inheritance (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 30 2015

Eligibility: Independent school districts; Private institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.113 -- Environmental Health; 93.865 -- Child Health and Human Development Extramural Research

Funding Opportunity Number: PAR-13-385

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support the development of comprehensive reference epigenomes for male and female gametes, and pre-implantation embryos after exposure to a particular environmental factor/insult. What is envisioned is the establishment of a compendium/atlas annotating epigenetic changes during various stages of spermatogenesis, oogenesis, and pre-implantation embryo development, the identification of the affected genes, and the characterization of any resulting phenotype in the offspring. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-13-385.html>

NIH Director's Early Independence Awards (DP5)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Jan, 30 2015

Expected Number of Awards: 10

Estimated Total Program Funding: \$4,000,000

Eligibility: Public and State controlled institutions of higher education; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Small businesses; Faith-based or Community-based Organizations

CFDA Number: 93.310 -- Trans-NIH Research Support

Funding Opportunity Number: RFA-RM-14-004

The NIH Directors Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-14-004.html>

4D Nucleome Imaging Tools (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 2, 2015

Estimated Total Program Funding: \$3,000,000

Eligibility: Small businesses; Private institutions of higher education; Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Public housing authorities/Indian housing authorities ; Faith-based or Community-based Organizations;

CFDA Number: 93.310 -- Trans-NIH Research Support

Funding Opportunity Number: RFA-RM-14-009

The purpose of this FOA is to support projects to develop tools and strategies for studying: 1. the three dimensional architecture of the nucleus in relationship to the topography of nuclear bodies and transcriptional machineries, 2. the structure and function of poorly characterized nuclear structures, or 3. the role of specialized proteins and RNAs in the assembly, organization, and function of nuclear bodies, nuclear structures, and specialized subnuclear domains. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-14-009.html>

Nucleomics Tools (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 2, 2015

Estimated Total Program Funding: \$3,000,000

Eligibility For profit organizations other than small businesses; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Small businesses; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.310 -- Trans-NIH Research Support

Funding Opportunity Number: RFA-RM-14-007

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate physical, chemical and biochemical approaches for measuring properties and dynamics of the three-dimensional organization of the genome that cannot be measured adequately using existing methodologies. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-14-007.html>

Innovative Technologies for Differential Diagnosis of Acute Febrile Illnesses (R21/R23)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 2, 2015

Estimated Total Program Funding: \$5,400,000

Eligibility: Public housing authorities/Indian housing authorities; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Independent school districts; Private institutions of higher education; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.855 -- Allergy, Immunology and Transplantation Research; 93.856 -- Microbiology and Infectious Diseases Research

Funding Opportunity Number: RFA-AI-14-062

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for early-stage translational research projects focused on the development of innovative, unbiased next generation, differential diagnostic technologies for acute febrile illnesses caused by infectious pathogens, excluding HIV. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-062.html>

Interdisciplinary Research to Understand the Vascular Contributions to Alzheimer's Disease (R01)

Granting Agency: National Institutes of Health
Current Closing Date for Applications: Feb 3, 2015
Estimated Total Program Funding: \$4,000,000

Eligibility: Public and State controlled institutions of higher education; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education;; Small businesses; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Private institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.866 -- Aging Research

Funding Opportunity Number: RFA-AG-15-010

The goal of this funding opportunity announcement is to support interdisciplinary research that will lead to a greater understanding of the mechanisms by which vascular factors contribute to the complex etiology of Alzheimer's disease. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-15-010.html>

Hepatitis C Cooperative Research Centers: Immunity to HCV Infection (U19)

Granting Agency: National Institutes of Health
Current Closing Date for Applications: Feb 3, 2015
Expected Number of Awards: 4

Estimated Total Program Funding: \$3,000,000

Eligibility: Public housing authorities/Indian housing authorities; Independent school districts; For profit organizations other than small businesses; State governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Faith-based or Community-based Organizations; Small businesses; Private institutions of higher education

CFDA Number: 93.855 -- Allergy, Immunology and Transplantation Research; 93.856 -- Microbiology and Infectious Diseases Research

Funding Opportunity Number: RFA-AI-14-045

The purpose of the Funding Opportunity Announcement (FOA) is to support research on the host immunological response to Hepatitis C Virus (HCV) infection with the goal of defining the immune requirements critical to a) protection against HCV infection, and b) successful clearance of HCV infection, conducted through Hepatitis C Cooperative Research Centers (HepC

Center(s)). **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-045.html>

NIDCD Planning Grant for Phase III Clinical Trials in Communication Disorders (U34)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 4, 2015

Eligibility: Public housing authorities/Indian housing authorities; Private institutions of higher education; Public and State controlled institutions of higher education; For profit organizations other than small businesses; Independent school districts; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.173 -- Research Related to Deafness and Communication Disorders

Funding Opportunity Number: PAR-12-124

The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting robust, well-designed, and well-executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between NIDCD project collaborator and investigator for a planning grant for phase III clinical trials of definitive efficacy. NIDCD Phase III Clinical Trials in Communication Disorders (U01) applications are accepted only from successful NIDCD Planning Grant for Phase III Clinical Trials in Communication Disorders (U34) awardees, unless NIDCD program staff agrees to accept a phase III clinical trial application from an investigator who has not used an NIDCD clinical trial planning grant first. The NIDCD Planning Grant for Phase III Clinical Trials in Communication Disorders (U34) is used to gather information and prepare a Manual of Procedures (MOP) (see <http://www.nidcd.nih.gov/research/clinicaltrials> for an example of a complete, detailed MOP). NIDCD Phase III Clinical Trials in Communication Disorders (U01) (PAR-12-123) applications must include a complete detailed MOP in the appendix. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-12-124.html>

NIDCD Planning Grant for Phase I/II/ III Clinical Trials in Communication Disorders (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 4, 2015

Eligibility: Public housing authorities/Indian housing authorities; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and; State controlled institutions of higher education; Independent school districts

For profit organizations other than small businesses; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.173 -- Research Related to Deafness and Communication Disorders

Funding Opportunity Number: PAR-12-123

The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting robust, well-designed, and well-executed clinical trials.

This funding opportunity announcement (FOA) supports a cooperative agreement between NIDCD project collaborator and investigator to support phase I and II clinical trials of preliminary efficacy and phase III clinical trials of definitive efficacy. Phase III clinical trial applications must include a complete detailed Manual of Procedures (MOP) in the appendix (see <http://www.nidcd.nih.gov/research/clinicaltrials> for an example of a complete, detailed MOP).

The NIDCD Planning Grant for Phase III Clinical Trials in Communication Disorders (U34) (PAR-12-124) may be used to gather information and prepare the MOP. **For more information, go to:** <http://grants.nih.gov/grants/guide/pa-files/PAR-12-123.html>

Development of a Microfluidic Platform for Blood Testing in Neonatal and Pediatric Patients SBIR (R43/R44)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 10, 2015

Eligibility: Small Businesses

CFDA Number: 93.839 -- Blood Diseases and Resources Research

Funding Opportunity Number: RFA-HL-14-026

This FOA encourages applications to develop microfluidic devices to analyze blood for factors related to the thrombotic, transfusion, and/or hemostatic status of pediatric/neonatal patients. Platforms should support clinical and/or research applications. Microfluidic designs that are multifunctional, with the capacity to perform multiple assays on a single blood sample, are of interest. Use of these devices could significantly reduce levels of phlebotomy-induced blood loss in pediatric/neonatal patients. **For more information, go to:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-026.html>

Geography and Spatial Sciences Program

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 12, 2015

Expected Number of Awards: 40

Estimated Total Program Funding: \$600,000

Eligibility Proposals may only be submitted by the following: -Universities and Colleges - Universities and two- and four-year colleges (including community colleges) accredited in, and having a campus located in, the US acting on behalf of their faculty members. Such organizations also are referred to as academic institutions. *Who May Serve as PI:DDRI proposals must be submitted with a principal investigator (PI) and a co-principal investigator (co-PI).

The PI must be the advisor of the doctoral student or another faculty member at the U.S. university where the doctoral student is enrolled. There is no limitation on the number of times that an individual may be the principal investigator on a DDRI proposal submitted to

GSS, either during a specific competition or over the course of her/his career. A doctoral student may submit a DDRI proposal to GSS to support her/his dissertation research only twice during her/his lifetime. A student and her/his advisor therefore should carefully consider what times during the student's graduate program are most appropriate for submission of a DDRI proposal.

CFDA Number: 47.075 -- Social, Behavioral, and Economic Sciences

Funding Opportunity Number: 14-538

As specified in the Geography and Spatial Sciences Program strategic plan, the goals of the NSF Geography and Spatial Sciences (GSS) Program are the following: To promote scientific research in geography and the spatial sciences that advances theory and basic understanding and that addresses the challenges facing society. To promote the integration of geographers and spatial scientists in interdisciplinary research. To promote education and training of geographers and spatial scientists in order to enhance the capabilities of current and future generations of researchers. To promote the development and use of scientific methods and tools for geographic research. The Geography and Spatial Sciences Program sponsors research on the geographic distributions and interactions of human, physical, and biotic systems on Earth. Investigators are encouraged to propose plans for research about the nature, causes, and consequences of human activity and natural environmental processes across a range of scales. Projects on a variety of topics qualify for support if they offer promise of contributing to scholarship by enhancing geographical knowledge, concepts, theories, methods, and their application to societal problems and concerns. As part of its effort to encourage and support projects that explicitly integrate education and basic research, GSS provides support to improve the conduct of doctoral dissertation projects undertaken by doctoral students enrolled in U.S. universities when the dissertation research is conducted in a scientifically sound manner and it offers strong potential for enhancing more general scientific knowledge. This solicitation addresses the preparation and evaluation of proposals for Doctoral Dissertation Research Improvement (DDRI) awards. Instructions for submission of proposals for regular research awards; proposals for awards for conferences, workshops, group-travel support, and community-development or community-serving activities; proposals for research coordination network (RCN) awards; and proposals for rapid-response research (RAPID) awards appear in another GSS solicitation (<http://xxx.nsf.gov>). **For more information, go to:** http://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf14538

Vascular Dysfunction in the Pathogenesis of Severe Malaria

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 13, 2015

Expected Number of Awards: 6

Estimated Total Program Funding: \$2,700,000

Eligibility Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Private institutions

of higher education; Public and State controlled institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.839 -- Blood Diseases and Resources Research

Funding Opportunity Number: RFA-HL-15-023

The purpose of this FOA is to solicit multiple-Program Director/Principal Investigator (PD/PI) applications that propose collaborative studies to address the role of vascular activation and dysfunction in the pathogenesis of severe malaria. Multidisciplinary teams of investigators are needed to identify pathways and regulatory mechanisms by which vascular factors contribute to the complex etiology of severe malaria.

For more information: <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-023.html>

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R21/R33)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 17, 2015

Eligibility Small businesses; Public and State controlled institutions of higher education; Private institutions of higher education; Independent school districts; For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.242 -- Mental Health Research Grants

Funding Opportunity Number: RFA-MH-15-300

The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support go/no-go decisions about further development or testing of the intervention. Studies of novel interventions include, but are not limited to behavioral, pharmacological, biologics-based, cognitive, device-based, interpersonal, physiological, or combined approaches. Support will be provided for up to two years (R21 phase) for preliminary milestone-driven testing and validating of the interventions mechanism of action, possibly followed by up to 3 years of support (R33 phase) for studies relating the mechanism to functional or clinical effects. Ultimately, this R21/R33 funding mechanism is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders. **For more information, go to:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-15-300.html>

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 17, 2015

Estimated Total Program Funding: \$3,000,000

Eligibility Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Independent school districts; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Private institutions of higher education; Public and State controlled institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.242 -- Mental Health Research Grants

Funding Opportunity Number: RFA-MH-15-310

The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support go/no-go decisions about further development or testing of the intervention. Studies of novel interventions include, but are not limited to behavioral, pharmacological, biologics-based, cognitive, device-based, interpersonal, physiological, or combined approaches. Support will be provided for testing and validating the interventions mechanism of action and for studies relating the mechanism to functional or clinical effects. Ultimately, this funding mechanism is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders. **For more information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-15-310.html>

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 17, 2015

Estimated Total Program Funding: \$9,000,000

Eligibility Public and State controlled institutions of higher education; Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Public housing authorities/Indian housing authorities; Independent school districts; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.242 -- Mental Health Research Grants

Funding Opportunity Number: RFA-MH-15-320

This Funding Opportunity Announcement (FOA) seeks to support investigator-initiated clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems -level services interventions to improve service access, engagement, quality, coordination, or delivery, with the goal of improved outcomes at the individual and population level. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. Applications must justify the potential impact of the proposed intervention/services models on practice and public health in terms of the magnitude of likely improvements in key outcomes (e.g., effect size, safety/tolerability profile, value and efficiency, and dissemination potential), as compared to existing approaches.

For more information <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-15-320.html>

Pilot Effectiveness Studies and Services Research Grants (R34)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 17, 2015

Estimated Total Program Funding: \$3,000,000

Eligibility For profit organizations other than small businesses; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Public housing authorities/Indian housing authorities; Private institutions of higher education); Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.242 -- Mental Health Research Grants

Funding Opportunity Number: RFA-MH-15-330

The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot research consistent with NIMHs priorities for: 1) effectiveness research on interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) innovative services research directions that require preliminary testing or development. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health and modify risk factors, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study. **For more information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-15-330.html>

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 17, 2015

Estimated Total Program Funding: \$9,000,000

Eligibility For profit organizations other than small businesses; Public and State controlled institutions of higher education; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.242 -- Mental Health Research Grants

Funding Opportunity Number: RFA-MH-15-325

This Funding Opportunity Announcement (FOA) seeks to support investigator-initiated collaborative clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems -level services interventions to improve service access, engagement, quality, coordination, or delivery, with the goal of improved outcomes at the individual and population level. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. Applications must justify the potential impact of the proposed intervention/services models on practice and public health in terms of the magnitude of likely improvements in key outcomes (e.g., effect size, safety/tolerability profile, value and efficiency, and dissemination potential), as compared to existing approaches. **For more information** <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-15-325.html>

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01)

Granting Agency: National Science Foundation

Current Closing Date for Applications: Feb 17, 2015

Expected Number of Awards: 5

Estimated Total Program Funding: \$5,000,000

Eligibility Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.242 -- Mental Health Research Grants

Funding Opportunity Number: RFA-MH-15-340

The purpose of this Funding Opportunity Announcement (FOA) is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support go/no-go decisions about further development or effectiveness testing of a targeted, scaled-up intervention. Intervention studies include, but are not limited to behavioral, cognitive, and interpersonal approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the interventions efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently- powered efficacy trial to determine the interventions potential for significant clinical benefit. **For more information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-15-340.html>

NIDCD Research on Hearing Health Care (R21/R33)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 24, 2015

Eligibility For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Independent school districts; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.173 -- Research Related to Deafness and Communication Disorders

Funding Opportunity Number: RFA-DC-14-001

This funding opportunity announcement (FOA) invites Exploratory/Developmental Phased Innovation (R21/R33) grant applications to support research and/or infrastructure needs leading to more accessible and affordable hearing health care (HHC). The proposed research aims should lead to the delivery of better healthcare access and outcomes and be directed to solutions that are effective, affordable and deliverable to those who need them. Outcomes and health services research are also responsive to this FOA. This FOA provides support for up to two years (R21 phase) for preliminary/development studies, followed by possible transition of up to four years of

expanded research and development support (R33 phase). The total project period for an application submitted in response to this FOA may not exceed five years. This FOA requires measurable R21 milestones. **For More Information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DC-14-001.html>

Multidisciplinary and Collaborative Research Consortium to Reduce Oral Health Disparities in Children: A Multilevel Approach (UH2/UH3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 27, 2015

Expected Number of Awards: 8

Estimated Total Program Funding: \$5,000,000

Eligibility Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Small businesses; Public housing authorities/Indian housing authorities; Private institutions of higher education; Independent school districts; ; Faith-based or Community-based Organizations

CFDA Number: 93.121 -- Oral Diseases and Disorders Research

Funding Opportunity Number: RFA-DE-15-006

The overall goal of this initiative is to establish effective interventions or programs to reduce or eliminate oral health disparities and inequalities in vulnerable U.S. children who are between 0 and 21 years of age. Multidisciplinary teams of investigators will refine and test an intervention or evaluate outcomes of an existing program or policy intended to reduce health disparities and inequalities. Community engagement and other partnerships are essential for the holistic, multilevel approaches required by this FOA. This research is intended to lead to identification, validation, dissemination and implementation of effective approaches to prevent disease or facilitate treatments, helping to reduce and ultimately eliminate oral health disparities and inequalities in children. This FOA will use the UH2/UH3 cooperative agreement award mechanism and runs in parallel with a companion FOA that solicits applications for the Data Coordinating Center (RFA-DE-15-007). Funding for an exploratory UH2 stage will be used for planning, feasibility testing, and developing study documents, including the study protocol and Manual of Procedures. UH2 projects that have met milestones will be administratively considered for transition to the UH3 implementation phase. Applicants responding to this FOA must address objectives for both the UH2 and UH3 phase **For More Information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-15-006.html>

Multidisciplinary and Collaborative Research Consortium to Reduce Oral Health Disparities in Children: Data Coordinating Center (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Feb 27, 2015

Expected Number of Awards: 1

Estimated Total Program Funding: \$2,200,000

Eligibility Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Small businesses; Public and State controlled institutions of higher education; Independent school districts; For profit organizations other than small businesses; Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.121 -- Oral Diseases and Disorders Research

Funding Opportunity Number: RFA-DE-15-007

The overall goal of this initiative is to establish effective interventions or programs to reduce or eliminate oral health disparities and inequalities in vulnerable U.S. children who are between 0 and 21 years of age. Multidisciplinary teams of investigators will refine and test an intervention or evaluate outcomes of an existing program or policy intended to reduce health disparities and inequalities. Community engagement and other partnerships are essential for the holistic, multilevel approaches required by this FOA. This research is intended to lead to identification, validation, dissemination and implementation of effective approaches to prevent disease or facilitate treatments, helping to reduce and ultimately eliminate oral health disparities and inequalities in children. This FOA solicits applications for the Data Coordinating Center (DCC) and runs in parallel with a companion FOA that solicits applications for the individual projects to be funded under a UH2/UH3 cooperative agreement mechanism (RFA-DE-15-006).

For More Information: <http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-15-007.html>

Planning Grants for Translational Research to Improve Obesity and Diabetes Outcomes (R34)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 2, 2015

Eligibility

Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Public and

State controlled institutions of higher education; Small businesses; Faith-based or Community-based Organizations

CFDA Number: 93.242 -- Mental Health Research Grants; 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: PAR-12-173

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Mental Health (NIMH) encourage NIH Clinical Trial Planning Grant Program grant (R34) applications from institutions/ organizations to develop and pilot test practical, sustainable, acceptable, and cost efficient adaptations of efficacious strategies or approaches prevent and treat diabetes and/or obesity. Research must target the prevention or reversal of obesity, prevention of type 2 diabetes, improved care of type 1 and type 2 diabetes, or the prevention or delay of the complications of these conditions. NIMH encourages research focused on people with severe mental illness (SMI), whose risk for obesity and type 2 diabetes is twice that of the general population. The approaches tested should have the potential to be widely disseminated to clinical practice, individuals and communities at risk. **For More**

Information: <http://grants.nih.gov/grants/guide/pa-files/PAR-12-173.html>

NIAMS Clinical Trial Planning Cooperative Agreement (U34)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 2, 2015

Eligibility Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Independent school districts; For profit organizations other than small businesses; Small businesses; Public housing authorities/Indian housing authorities; Faith-based or Community-based Organizations

CFDA Number: 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research

Funding Opportunity Number: PAR-14-199

This Funding Opportunity Announcement (FOA) will support planning cooperative agreements (U34) (hereafter called planning grants) for investigator-initiated clinical interventional trials. The U34 planning grant is designed to permit the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of a U34 planning grant is recommended prior to submission of a clinical trial through a U01 clinical trial implementation grant application that will support the actual implementation and conduct of the study. Consultation with NIAMS staff is strongly encouraged prior to the submission of the U34 application. The trials must be hypothesis-driven, milestone-defined, related to the research mission of the NIAMS and considered high priority by the Institute. **For More Information:** <http://grants.nih.gov/grants/guide/pa-files/PAR-14-199.html>

NIAMS Clinical Trial Implementation Cooperative Agreement (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 2, 2015

Eligibility Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses); Faith-based or Community-based Organizations

CFDA Number: 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research

Funding Opportunity Number: PAR-14-200

This Funding Opportunity Announcement (FOA) invites cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with a U34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without having applied for a U34. Consultation with NIAMS staff is strongly encouraged prior to the submission of the clinical trial implementation U01 application. The NIAMS expects such trials to be hypothesis driven, milestone-defined, related to the research mission of the NIAMS, and considered high-priority by the institute. **For More Information:** <http://grants.nih.gov/grants/guide/pa-files/PAR-14-200.html>

Consortium on Beta-cell Death and Survival (HIRN-CBDS) (UC4)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 2, 2015

Estimated Total Program Funding: \$8,000,000

Eligibility Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Public housing authorities/Indian housing authorities; Native American tribal governments (Federally recognized); Small businesses; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-021

This Funding Opportunity Announcement (FOA) requests applications for the development of medium- to high-throughput "omics" technologies that can be used to explore human pancreatic tissues with single cell- or near single cell- resolution. Successful applicants will join the Consortium on Beta cell Death and Survival (CBDS), whose mission is to identify the mechanisms of beta cell stress and destruction central to the development of Type 1 Diabetes

(T1D) in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and preventing the progression towards autoimmunity. CBDS is part of the Human Islet Research Network (HIRN). **For More Information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-021.html>

Limited Competition for the Continuation of the SEARCH for Diabetes in Youth Cohort Study (UC4)

Granting Agency: National Institutes of Health
Current Closing Date for Applications: Mar 10, 2015
Expected Number of Awards: 1

Estimated Total Program Funding: \$14,000,000

Eligibility This FOA is a limited competition for continuation of the SEARCH Cohort study, which was previously funded in response to RFA-DP-10-001. Only the currently funded SEARCH Data Coordinating Center is eligible to apply.

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research; 93.945 -- Assistance Programs for Chronic Disease Prevention and Control

Funding Opportunity Number: RFA-DK-14-508

The purpose of this Funding Opportunity Announcement (FOA) is to continue the SEARCH for Diabetes in Youth Study. The overarching goal of SEARCH is to provide population-based data on the incidence and prevalence of diabetes and its complications in U.S. youth. SEARCH has recruited a cohort of youth with diabetes who have been followed longitudinally. The purpose of this FOA is to continue follow-up of the SEARCH cohort to understand the clinical course of youth-onset diabetes, including the incidence of acute and chronic complications, including mortality, and processes of care and quality of life. **For More Information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-508.html>

FY 2015 NAGPRA Grant Program

Granting Agency: National Institutes of Health
Current Closing Date for Applications: Mar 11, 2015
Expected Number of Awards: 1

Estimated Total Program Funding: \$14,000,000

Eligibility Private institutions of higher education; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

CFDA Number: 15.922 -- Native American Graves Protection and Repatriation Act

Funding Opportunity Number: P14AS00393

The National NAGPRA Program assists the Secretary of the Interior with some responsibilities under NAGPRA. Section 10 of NAGPRA authorizes the Secretary of the Interior to make grants to museums, Indian tribes, and Native Hawaiian organizations for the purposes of assisting in

consultation, documentation, and repatriation of Native American cultural items, including human remains, funerary objects, sacred objects, and objects of cultural patrimony.

For More Information: <http://www.nps.gov/nagpra/grants/index.htm>

Integrated Preclinical/Clinical ADIS Vaccine Development Program (IPCAVD) (U19)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 13, 2015

Eligibility Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Public housing authorities/Indian housing authorities; For profit organizations other than small businesses; Small businesses; Public and State controlled institutions of higher education; Private institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.855 -- Allergy, Immunology and Transplantation Research; 93.856 -- Microbiology and Infectious Diseases Research

Funding Opportunity Number: PAR-14-122

The goal of the IPCAVD Funding Opportunity Announcement (FOA) is to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. The IPCAVD program is designed to enable a multi-disciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through CGMP manufacture/testing/product release and into clinical trials. A preclinical research application alone is not sufficient for this announcement. Awards will provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the first 5 years of the award. However, this funding opportunity will not provide funds for conducting the clinical studies; applicants are encouraged to collaborate with NIAID-supported clinical trial networks or to develop other relationships to support the clinical studies. Investigators are expected to begin clinical studies no later than year five of the award. **For More Information:** <http://grants.nih.gov/grants/guide/pa-files/PAR-14-122.html>

AHRQ Small Research Grant Program (R03)

Granting Agency: Agency for Health Care Research and Quality

Current Closing Date for Applications: Mar 16, 2015

Eligibility Public and State controlled institutions of higher education; Private institutions of higher education; City or township governments; Faith-based or Community-based Organizations

CFDA Number: 93.226 -- Research on Healthcare Costs, Quality and Outcomes

Funding Opportunity Number: PAR-10-168

Purpose. This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications, and expresses AHRQ portfolio priority areas of interest for ongoing small research projects. The R03 grant mechanism supports different types of health services research projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and, development of new

research technology. Mechanism of Support. This FOA will use the AHRQ Small Research Grant (R03) mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. **For More Information:** <http://grants.nih.gov/grants/guide/pa-files/PAR-10-168.html>

Improving Diabetes Management in Young Children with Type 1 Diabetes (DP3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 18, 2015

Estimated Total Program Funding: \$3,500,000

Eligibility Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Small businesses; Independent school districts; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Private institutions of higher education; Faith-based or Community-based Organizations

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: RFA-DK-14-022

The goal of this Funding Opportunity Announcement (FOA) is to support research to develop, refine, and pilot test innovative strategies to improve diabetes management in young children with type 1 diabetes (5 years old and under). At the end of the funding period, there should be a well-developed and well-characterized intervention that has been demonstrated to be safe, feasible to implement, acceptable in the target population, and, if promising, ready to be tested in a larger efficacy trial. **For More Information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-022.html>

Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 19, 2015

Eligibility Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Faith-based or Community-based Organizations

CFDA Number: 93.398 -- Cancer Research Manpower

Funding Opportunity Number: PAR-14-152

This Funding Opportunity Announcement (FOA) invites P20 planning grant applications for the implementation of collaborative partnership awards between Institutions serving communities with cancer health disparities and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). For the purpose of this FOA, "the Institution(s)" will refer to academic or other organizations serving communities with cancer health disparities. This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, training/career development, and education. A major goal of the NCI P20 partnership awards is to provide support for investigators at the Institutions and Cancer Centers to conduct cancer pilot projects and training and education programs. The pilot projects and programs will allow awardees to obtain preliminary data and lead to competitive grant applications for funding by the NIH/NCI and/or other Federal/Non-Federal agencies. **For More Information:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-14-152.html>

Type 1 Diabetes Complications IMPACT Award (DP3)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 19, 2015

Estimated Total Program Funding: \$20,000,000

Eligibility Special district governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; For profit organizations other than small businesses; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Private institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

Small businesses; Faith-based or Community-based Organizations

CFDA Number: 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

Funding Opportunity Number: PAR-14-152 RFA-DK-14-017

This FOA encourages research applications from institutions/organizations proposing innovative studies focused on major obstacles to developing therapeutic approaches for complications of Type 1 Diabetes. **For More Information:** <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-017.html>

Opportunities for Collaborative Research at the NIH Clinical Center (U01)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 20, 2015

Eligibility For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Small businesses; Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations;

CFDA Number: 93.121 -- Oral Diseases and Disorders Research; 93.172 -- Human Genome

Research; 93.173 -- Research Related to Deafness and Communication Disorders; 93.233 -- National Center on Sleep Disorders Research; 93.242 -- Mental Health Research Grants; 93.273 -- Alcohol Research Programs; 93.279 -- Drug Abuse and Addiction Research Programs; 93.286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health; 93.393 -- Cancer Cause and Prevention Research; 93.394 -- Cancer Detection and Diagnosis Research; 93.395 -- Cancer Treatment Research; 93.396 -- Cancer Biology Research; 93.399 -- Cancer Control; 93.837 -- Cardiovascular Diseases Research; 93.838 -- Lung Diseases Research; 93.839 -- Blood Diseases and Resources Research; 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research; 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.855 -- Allergy, Immunology and Transplantation Research; 93.856 -- Microbiology and Infectious Diseases Research; 93.865 -- Child Health and Human Development Extramural Research; 93.879 -- Medical Library Assistance

Funding Opportunity Number: PAR-13-358

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and

For More Information: <http://grants.nih.gov/grants/guide/pa-files/PAR-13-358.html>

NIAMS Small Grant Program For New Investigators (R03)

Granting Agency: National Institutes of Health

Current Closing Date for Applications: Mar 20, 2015

Estimated Total Program Funding: \$1,500,000

Eligibility Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Independent school districts; Small businesses; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Faith-based or Community-based Organizations;

CFDA Number: 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research

Funding Opportunity Number: PAR-12-045

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is seeking small grant (R03) applications to stimulate and facilitate the entry of promising new investigators into research on arthritis and musculoskeletal and skin diseases and injuries. This FOA will provide support for pilot research that is likely to lead to a subsequent individual research project grant (R01). Clinical trials of any phase will not be supported by this FOA. **For More**

Information: <http://grants.nih.gov/grants/guide/pa-files/PAR-12-045.html>